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Following trauma from high-energy blasts, a population of multipotent progenitor cells 
(MPCs) can be derived from the debrided muscle tissue. Given the non-intrusive nature of MPC 
isolation, MPCs represent an attractive clinical alternative to the more widely used mesenchymal 
stem cells derived from bone marrow and other tissue sources. This dissertation presents work 
which further defines the utility and limitations of MPCs in applications relevant to the repair of 
extremity injuries, including angiogenesis, peripheral nerve repair, and bone formation.   
The secretome of MPCs enhanced in vitro angiogenesis, in a manner dependent on MPC 
production of vascular endothelial growth factor-A (VEGF). Encapsulated within mechanically 
tunable injectable hydrogel constructs, MPCs retained strong pro-angiogenic activity when 
implanted in vivo, supporting potential clinical use when enhanced vessel recruitment is desired. 
Neurotrophically-induced MPCs, in combination with endothelial cells (ECs) co-cultured 
on aligned, nanofibrous scaffolds or via secretome interactions, supported neurite outgrowth and 
extension of chick embryonic dorsal root ganglia. These findings suggest that products of 
induced MPCs may be useful to enhance nerve guide conduit-based repair of peripheral nerves. 
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ECs influenced earlier and stronger MPC osteogenic gene expression, and IL-1β was 
associated with increased mineralization. The use of MPCs in bone replacement applications 
may thus result in mineralization without functional bone formation, depending on the level of 
inflammation at the site of construct implantation. 
Taken together, this work extends the potential utility of MPCs for limb regenerative 
applications, especially for enhanced vessel or nerve recruitment. Caution must be exercised as 
MPCs may be influenced towards a mineralizing phenotype by the tissue environment, likely 
contributing to the heterotopic ossification pathology commonly seen following blast trauma. 
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1.0  INTRODUCTION 
Recovery following injury on the modern battlefield presents specific challenges. The volume of 
tissue loss combined with the unique injury mechanism and resulting disorganized wound make 
the restoration of function an admirable if extremely difficult goal. Before therapies can be 
developed, the unique role of autologous multipotent progenitor cells in both healing and 
pathologies must be examined.  
1.1 MODERN COMBAT CASUALTIES 
Because of recent advances in body armor technology, tourniquet use, improved time-to-
treatment, and rapid evacuation to well-equipped hospitals, military combatants are surviving a 
greater number of more intense combat-related injuries1. Improvements in thoracic-protection 
equate to a reciprocal increase in severity of extremity- and head/brain-trauma, with greater 
involvement of multiple organ systems in almost all combat-related injuries when compared to 
previous armed conflicts2. A majority (>50%) of combat-related wounds involve the 
extremities1. 
In contrast with traumatic injuries of the limb in the American civilian population, 
combat wounds leave very little tissue to stabilize and repair2. The volume and extent of tissue 
lost during combat and subsequent surgical interventions suggests that regeneration and 
replacement are more desirable goals; to date, these strategies have attempted to exploit the same 
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mechanisms observed in tissue repair. Adult stem cells have generated intense interest among 
military researchers due to the young and otherwise healthy nature of most military patients, 
factors that correlate with stem cell efficacy3; the mean age of combat injury for Operation Iraqi 
Freedom (OIF) and Operation Enduring Freedom (OEF) was 23.3 years4.  
1.1.1 Immediate combat casualty care 
During 2001-2010, an average of 4000 American military combatants per year were non-
mortally wounded in-theater during OIF and OEF4. Wound treatment within-theater focused on 
practical patient stabilization; modern military medics were trained to first address bleeding, 
through the use of advanced tourniquets and hemostatic dressings, followed by minimal airway 
and management only if the patient was unconscious1. In the absence of hostile fire or adverse 
weather, helicopter transport allowed removal within one hour to battalion aid stations, equipped 
with a blood bank and at least four surgeons, or to better-equipped combat support hospitals. 
Field dressings were removed and patient injuries treated surgically. Depending on prognosis, 
patients were then evacuated to a Regional Hospital in Germany or, ultimately, to United States 
(US) military medical centers1; transport duration from theater to US hospital ranged from 36 
hours to 1 week5. Commonly-affected systems and combat-specific complications are described 
in Table 16.  
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Table 1: Multiple systems may be injured during modern military combat operations6  
 
Affected system Combat-specific complications 
Vision Photoreceptor and retinal neuron loss 
Auditory Sensory hair loss, vertigo 
Vasculo-
pulmonary/cardiac Embolism, hemorrhage, or contusion 
Central nervous: 
Brain/spinal cord Physical and psychological devastation 
Peripheral nervous Limited function, neuropathic pain 
Skin graft Lack of coverage/scar formation 
Musculoskeletal Limited mobility, pain, heterotopic ossification 
 
While solutions to repair each system are being actively investigated, blast extremity 
injuries typically involve damage to several of these systems, necessitating surgical interventions 
aimed at ensuring patient survival and limb retention over limb repair. 
1.1.2 Follow-up extremity care: limb salvage versus amputation and MPC-isolation 
As part of successful wound and infection management, a point of concern in its own right as 
recalcitrant bacterial and fungal infections cause more than 25% of injured combatants to face 
revision surgery7, foreign contaminants that could be identified were removed from blast-
damaged tissue through a process of vigorous surgical debridement, termed wound excision8. 
During this procedure, all mangled and 2-3 mm of healthy tissue were excised from the injured 
tissue in an effort to promote healing and decrease the rate of infection9, and the area was washed 
with copious amounts of (often) pressurized sterile saline; this treatment was repeated until the 
wound closed. From the healthy wound margins, plastic-adherent traumatized-muscle-derived 
multipotent progenitor cells (MPCs) could be isolated; they will be discussed in further detail in 
subsequent sections. 
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Despite these prophylactic interventions, approximately 140 military patients per year 
(about 3.5%) required lower-limb amputations due to combat-related wounds10.  Similar to the 
civilian population, speedy resolution to the question of amputation or limb salvage was key to a 
positive patient outcome; attempted limb salvage followed by amputation (>90 days after injury) 
was associated with higher rates of psychological as well as physical problems, including 
infection and pain compounded by PTSD and substance abuse11.  Clearly, more effective limb 
salvage techniques are needed. 
1.1.3 Extremity complications 
A recent study of military personnel who underwent amputation versus limb salvage showed that 
amputees typically recovered more musculoskeletal function than limb salvage patients, possibly 
due to advances in prostheses and early, focused rehabilitation12. Orthopedic complications 
account for the majority of long-term military disabilities13; this indicates that vast improvements 
to limb salvage techniques are required, particularly focusing on functional restoration of the 
limb. 
In a thorough discussion focusing on extremity-related consequences of combat injury, a 
military panel identified six broad types of complications that required revision surgery; three 
topics described musculoskeletal complications with two, posttraumatic osteoarthritis and 
heterotopic ossification (HO), involving excessive and accelerated formation of bone. Another 
section on complex limb injuries described the need to support vascularization and encourage 
nerve regeneration, both in the context of limb salvage and transplant support14. Twenty-five 
percent of injured Vietnam veterans suffered peripheral nerve complications, and the incidence 
from recent conflicts is likely to be higher given the higher energy injury mechanisms discussed 
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previously6. These continued complications highlight the great need for and interest in improved 
therapies specifically applicable to a recovering combatant. 
1.1.4 Heterotopic ossification 
In up to 60% of military limb salvage or amputation cases, excess bone formation through 
heterotopic ossification was noted, typically in muscle or other soft tissue15. If the ossification 
became painful or began to affect joint function, the bony pieces were removed with surgical 
excision/revision surgery. Military lower-extremity excision rates were initially reported to be 
18.7%16; in one study that involved closer post-operative monitoring and aggressive early 
excision, the excision rate climbed to 40%7. From the same group, upper-extremity incision rates 
agreed with the earlier number, remaining at 19%, despite radiographic evidence of HO in up to 
60% of the patients. By contrast, a second surgical excision was required in ~6% of HO cases in 
the civilian population. This suggest an injury mechanism, unique to blast-trauma, which 
supports the development of HO. 
While much is still unknown about the mechanisms that lead to heterotopic ossification, 
attempts to isolate the cellular causes of combat-associated HO have related the disease to 
fibrodysplasia ossificans progressiva (FOP), which allows cluster of differentiation (CD)34+ 
endothelial cell progenitors (EPCs) to transition to multipotent and eventually ossifying cells 
through the actions of activin17. Similarities in cellular activity and gene expression between 
FOP and tissue-resident stem cells will be discussed in the section MPCs. 
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1.2 NORMAL WOUND HEALING 
Discussions of dysregulated or enhanced healing rely on a thorough understanding of normal 
wound healing. Typically used to describe skin repair, wound healing processes apply to many 
other tissues as the initiating events, infiltrating cells, and cascade of immune- and tissue-
modulating factors are common to all injuries. Following that discussion, specific considerations 
for angiogenesis, osteogenesis, and neurotrophic support will be discussed.  
Because of the intimate link between delicate capillaries and all vascularized tissues, 
normal wound healing begins with an injury-associated blood leakage; in the adult, wound 
healing ends with the formation of non-functioning fibrous scar tissue18. Regardless of the 
injured tissue, this scar represents a sub-optimal tissue patch, exhibiting different mechanical and 
functional properties when compared to the surrounding tissue19. 
1.2.1 Initiation: hemostasis and coagulation 
Within the first few hours following injury, blood and lymph flush the wound of invading 
microorganisms and antigens; short times for vasoconstriction couple with extrinsic (tissue 
factor-factor VIIa-initiated) and intrinsic (platelet-collagen initiated) mechanisms to polymerize 
fibrin from fibrinogen and thrombin precursors, trapping platelets and their stores of 
multifunctional factors. Invading leukocytes and platelets release factors triggering: 
inflammation (interleukin [IL]-1α, IL-1β, IL-6, and tissue necrosis factor [TNF]-α), collagen-
synthesis (basic fibroblast growth factor [FGF-2], insulin-like growth factor [IGF}-1, 
transforming growth factor [TGF]-β), fibroblast-myofibroblast transition (TGF-β), angiogenesis 
(FGF-2, vascular endothelial cell growth factor [VEGF], hypoxia inducible factor [HIF]-1α, 
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TGF-β), and support re-epithelialization (epidermal growth factor [EGF], FGF-2, IGF-1, TGF-
α)20.  
1.2.2 Migration: inflammation 
During the early part of the inflammatory phase, neutrophils and macrophages are recruited and 
present for 2-5 days if no infection is present; during that time, the neutrophils degrade bacteria 
and clear necrotic tissue through protease secretion and phagocytosis20. Neutrophils release 
several classes of antimicrobial compounds, including reactive oxygen species, which may also 
limit the survival and function of resident multipotent cells21. In addition, neutrophils secrete 
VEGF and IL-8, which serve multiple functions including recruiting angiogenic cells and 
causing neutrophil apoptosis, respectively20. Neutrophils can also recruit monocytes and 
macrophages by releasing some of the same factors secreted by platelets and leukocytes (TNF-α, 
IL-1β, and IL-6)18. Macrophages phagocytose pathogens and cell debris, including apoptotic 
neutrophils, and can initiate the proliferative phase of wound healing by secreting TGF-β122. 
1.2.3 Proliferation 
Macrophages have the unique power to either promote or resolve inflammation through the 
production of TGF-α, TGF-β, FGF-2, platelet-derived growth factor (PDGF), and VEGF, which 
promote cell proliferation and the synthesis of extracellular matrix (ECM)20. Through these 
cytokines, macrophages recruit circulating monocytes and stimulate fibroblasts to proliferate, 
increasing wound cellularity23. 
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1.2.4 Remodeling 
Finally, re-epithelialization occurs between 3-10 days after wounding, initiating capillary 
sprouting and angiogenesis, the growth of new vessels from existing vessels, within the wound. 
Regulatory cytokines interferon (IFN)-γ and TGF-β promote the deposition of the new ECM, 
including collagen and fibronectin. Epithelial and non-epithelial cells at the wound edges release 
EGF, keratinocyte growth factor [KGF], IGF-1, and nerve growth factor [NGF]18. 
1.3 VASCULAR CONSIDERATIONS 
Vascular function is critical to life on the macroscopic and microscopic scale. Hypoxia or 
inflammation in the surrounding tissue typically results in the production of VEGF or stromal-
derived factor (SDF)-1, which are chemotactic for microvascular endothelial cells (ECs) as they 
branch from the capillary network24. Key events associated with vascular remodeling are 
summarized in Figure 125 and below. 
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Figure 1: ECs respond to soluble growth factors and blood flow, initiating sprouting 
angiogenesis  
(A) Tip cells sprout and migrate away from existing vessels, guided by factors including VEGF 
and SDF-1 released by tissues that require vascularization; tip cell fusion and stalk cell 
rearrangement, followed by (B) blood flow-induced vessel remodeling, results in organized and 
patent vascular structures. Reprinted with permission from Cell, 146/6, Potente M, Gerhardt H, 
Carmeliet P, Basic and therapeutic aspects of angiogenesis, 873-87, 2011, with permission from 
Elsevier. 
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1.3.1 Initiation 
VEGF signaling is one of the primary initiators of angiogenic capillary sprouting26. Tip cells, 
expressing VEGF-receptor (VEGFR-2) and low levels of Notch (a transmembrane receptor) but 
high levels of the Notch ligand Delta-like ligand-4, laterally inhibit neighboring cells from 
responding to VEGF.  VEGF-VEGFR-2 binding, in addition to VEGFR-3 and neuropilin (NRP)-
1, initiates filopodia extension by tip cells27. These factors signal ECs, normally ensconced 
within layers of basement membrane and stabilizing mural cells, to degrade the local ECM and 
become motile. This matrix metalloproteinase (MMP)-mediated degradation, in addition to 
physically freeing ECs, releases matrix-bound angiogenic factors; some have hypothesized that 
the released mural cells, or pericytes, form resident multipotent/stem cells that are observed in 
many tissues28. 
1.3.2 Migration 
One tissue-released factor, SDF-1, further stimulates EC tip cells to produce exploratory 
filopodia and move along angiogenic factor gradients25. Attracted by VEGF and SDF-1, tip cells 
move through the degraded matrix while remaining anchored to trailing, lumen-less stalk cells 
throughout their explorations; stalk cells, in turn, remain anchored to the fully functioning 
vasculature29.  
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1.3.3 Proliferation and remodeling 
Stalk cells have the ability to proliferate and form new branches and tubes, as required by the 
needs of the tissue. The anastomosis formed by the fusion of two tip cells completes the vascular 
circuit. The resulting blood vessel network initially forms a disorganized plexus, but subsequent 
blood flow induces remodeling of the vascular network and maturation of the stalk and tip cells 
into normally functioning vessel ECs30. Mural cells, which may include tissue-resident 
multipotent cells, attracted by EC-secreted BB isoform of PDGF, wrap around and stabilize the 
EC networks24.  
1.3.4 Inflammation and angiogenesis regulation 
Many factors, especially those released during inflammation including IL-1β and TNF-α, have 
the ability to disrupt connections in capillary networks. This allows invading blood and immune 
cells easy passage into the damaged tissue. If prolonged, vascular disruption can restrict normal 
healing, as is seen with chronic inflammation, keeping tissue in an endless loop of collagenous 
matrix deposition and fibroblast proliferation with poor vessel organization31. 
VEGF responsiveness is key to angiogenic cell maintenance and function, as well as 
VEGF’s function in other aspects of both wound healing and normal tissue function32. This 
responsiveness can be regulated at several points by the VEGF-responsive cells through the 
expression of different VEGF receptors33.  As was discussed above, VEGF binding with 
VEGFR2 binding typically causes cell migration and proliferation. Neuropilin binding to VEGF 
may be responsible for the observed migratory effect29,34. VEGFR-1, produced in both a 
membrane-bound signaling and a decoy soluble form, is thought to oppose these effects by 
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tightly binding VEGF. Membrane-bound VEGFR-1 signals only weakly despite its high affinity 
for VEGF, sequestering excessive amounts of the molecule35.  Changes in the relative amount of 
surface-expression of all of these receptors can change the responsiveness of the target cells to 
VEGF therapies, as has been noted in cancer models36. 
1.3.5 Experimental models of angiogenesis 
Because of the plethora of functions required of ECs, in particular, and the vascular system as a 
whole, in vitro angiogenesis assays test a variety of responses. Many of the assays involve the 
seeding of ECs onto or inside an extracellular matrix-rich environment37, typically collagen type 
I, laminin, or commercially-available growth factor-reduced Matrigel, a tumor-derived ECM. 
Many cell types will form cords or tubes in this context, depending on the cell seeding density, 
but EC network formation is particularly dynamic, regressing within a few hours to clustered 
islands of cells in the absence or blockade of pro-angiogenic stimuli 38.  
EC non-specific migration can be examined with the scratch assay39. Chemotactic EC-
migration can be examined using the Transwell/Boyden chamber40 assay which restricts cell 
movement along a factor gradient using a barrier with precisely-sized pores41; when ECM is used 
to  coat these pores, further restricting EC migration, zymogen assays or zymograms can help to 
elucidate specific MMPs responsible for matrix degradation42. 
Occupying a unique position between in vivo and in vitro assays, the chick 
chorioallantoic membrane (CAM) assay is another highly sensitive angiogenesis model that 
allows observation of capillary migration into constructs. Following careful transfer of a chick 
embryo from the egg shell to a petri dish at incubation day 3, the day 8 shell-less CAM (Figure 
2)43 sandwiches an extensive, dynamic capillary plexus between the inner allantoic and relatively 
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flat outer chorionic membranes that can be subjected, for up to 4 additional days, to pro- or anti-
angiogenic stimuli44. Multiple factor- or cell- depots, as well as appropriate controls, can then be 
exposed to identical oxygen tension and systemic embryonic circulation45. It is possible to test 
the angiogenic activities of cells sourced from widely-varying species, including humans, with 
the CAM assay since the chick immune system is not yet fully developed46. To minimize cell 
migration and maximize the observable CAM vessel recruitment, depots should restrict the 
movement of encapsulated cells. This allows the free diffusion of secreted factors and invasion 
of the relatively small avian vessels. 
 
 
 
Figure 2: Chick embryonic chorioallantoic membrane (CAM) assay system.  
The (A) shell-less/ex ovo CAM assay offers a wide viewing surface on which several growth 
factor- or cell- depots may be deposited. Vasculature supplying the embryo (B) is easily visible 
under microscopy. Embryos can remain viable for up to 16 days ex ovo; with permission from 
JoVE, modified from Yalcin, et al 43,47. 
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1.4 PERIPHERAL NERVE CONSIDERATIONS 
Nerves and blood vessels are intimately connected, both in development and in the 
adult32. They exhibit structural similarities and signal using some of the same molecules. 
Macroscopically, nerves bundle multiple individual neurons, with supporting Schwann cells, 
protective sheaths, and blood vessels, into neurovascular units48. Nerves and blood vessels 
regulate their responsiveness to paracrine signals, especially VEGF, by adjusting production of 
both decoy receptors, such as VEGFR-1, or soluble forms of active receptors such as sVEGFR-
249  or sNRP150. This suggests that pro-angiogenic therapies involving VEGF might also 
positively affect nerve growth and extension. Single neurons are encapsulated by Schwann cells 
which secrete trophic and maintenance factors in addition to protective myelin. Successive 
bundling of nerves and blood vessels into the endoneurium, perineurium, and epineurium 
maintain physical and nutrient support of the nerves51. 
1.4.1 Peripheral nerve injuries with combat considerations 
Nerve injuries associated with combat-related trauma contribute to compromised functional 
outcomes and major disability52,53.  In terms of the final outcome, one study found that in a 
cohort of patients that sustained upper limb nerve injuries, persistent weakness (84%), sensory 
deficit (69%), and chronic pain (24%) resulted from the injury54. In an earlier study of patients 
requiring vascular repair following a gunshot injury, 39% achieved a normal extremity, 
compared with only 7% if there was an associated peripheral nerve injury in the same limb55. As 
with poor limb function outcomes, peripheral nerve injury-induced morbidity resulted in reduced 
military preparedness, early discharge, poor reintegration into civilian life, and may contribute to 
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the wounded warriors’ higher rates of depression and suicide. A summary of the relevant aspects 
of nerve injury and healing is described below. 
1.4.2 Classification of nerve injuries 
Nerve injuries are classified in terms of degree of injury using the Seddon (3-point) or 
Sunderland (5-point) scale56,57. The lowest scores indicate damage to axons without axonal 
severance; if the injury is allowed to heal, return of nerve function is likely. Scores ≥3 on either 
scale indicate nerve damage that will be slow or unlikely to heal as the damage has extended 
from individual neurons to the nerve structure. Healing is summarized in Figure 358 and below. 
 
 
 
Figure 3: The four stages of nerve healing following injury rely on the activities of Schwann 
cells 
Following injury (A), Schwann cell-mediated degradation (B) clears the way for the extending 
axon(C). Schwann cells secrete a provisional matrix, termed bands of Bungner, which guides the 
growth cones of extending axons (D). Throughout this process Schwann cells secrete several 
factors to recruit nerves or sustain nerve survival. Reprinted with permission from Muscle and 
nerve, 13/9, Seckel B, Enhancement of peripheral nerve regeneration, 785-800, 1990, with 
permission from Elsevier. 
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 1.4.3 Migration/Stage I 
Although less pronounced than in other systems, nerve tissue migration initially involves 
retraction and sealing of the proximal and distal ends of the broken nerve axons. Additionally, 
Schwann cell-mediated, calcium-dependent degradation of the cell material, particularly myelin, 
contribute to Wallerian degeneration51. Currently, nerve regeneration is limited to the migratory 
capacity of the proximal nerve stump; that stump is most effectively recruited by factors released 
by the distal stump, discussed below59. Assuming neuron cell body survival, proximal stump 
migration continues throughout the nerve healing process and can last up to two years60.  
1.4.4 Inflammation/Stage II 
The remaining Schwann cells release cytokines that promote inflammatory cell infiltration and 
damaged tissue clearance, discussed above. Myelin clearance is especially critical to the eventual 
growth of nerves61. Once cleared, the lesion defines the gap that must be crossed by sprouting, 
exploratory axons to re-innervate the target organ; the maximum growth rate of neurons has been 
observed to be about one inch per month62. This slow growth rate may be further limited by 
fibrotic scar formation, and over extended time, correlated to the length of a critically-sized 
nerve defect (3-5 cm)63, the target tissue and Schwann cells may lose their abilities to support 
reinnervation64. 
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1.4.5 Proliferation/Stage III 
Schwann cells next proliferate, emerging from the proximal and distal axon stump and 
repopulating the gap leading to the distal nerve end.  After a sufficient number of Schwann cells 
repopulate this area, they begin to align across the gap, forming bands of Büngner that serve as a 
scaffold to guide sprouting axons to the end organ. Scar formation can block this process and 
lead to painful neuromas and distal tissue atrophy. 
1.4.6 Remodeling/Stage IV 
Schwann cells within the bands of Büngner secrete a number of neurotrophic factors that assist 
with axonal sprouting, guidance and survival.  These factors include NGF, brain-derived 
neurotrophic factor (BDNF), ciliary neurotrophic factor (CNTF), and glial cell line-derived 
neurotrophic factor (GDNF)65. Importantly, Schwann cells also produce VEGF which supports 
both the vasculature supplying the nerve and the neurite extensions themselves, which express 
both VEGFR-2 and NRP-166. These cytokines have been shown to be important for sciatic nerve 
regeneration and remyelination, as well as survival of other motor and sensory neurons67.  
 
1.4.7 Standard treatment of nerve injuries 
Three autologous strategies are currently used to treat nerve injuries: (1) direct nerve repair (i.e., 
proximal-to-distal end tensionless suturing), (2) the gold standard neural autograft repair, in 
which a nerve of similar type and size is excised and interposed between the proximal and distal 
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ends of the severed nerve, and (3) biological autograft repair, in which another tissue such as an 
artery or vein is placed within the gap to support nerve repair.  
Although ideal, direct nerve repair (Strategy 1) is rarely possible in both civilian and 
military nerve repair applications as it is only indicated in cases of sharp nerve division with 
minimal gap (<2.5 mm), intact blood supply, and soft-tissue coverage. Autologous grafting of 
neural or vascular tissue (Strategies 2 and 3) may result in donor-site morbidity and are 
associated with recovery rates of just 50%68. For the blast-injured combatant, adequate donor 
tissue may not be available. 
1.4.8 Alternative strategies for nerve repair 
While size-matched allogeneic nerves or blood vessels69 may be utilized in civilian populations 
as a form of nerve graft, graft acceptance requires long-term immunosuppression that could 
prove fatal to the blast-injured patient facing severe infection risks. Sterile nerve guide conduits 
are an alternative surgical treatment option that does not further tax the patient but are associated 
with poorer outcomes; several strategies have been employed clinically to maximize patient 
functional recovery70, as detailed below. 
Improvements aimed at treating peripheral nerve damage usually involve increasing the 
degree to which the synthetic scaffold mimics native, healthy nerve architecture, cell content, or 
Schwann cell growth factor content. Clinically-approved nerve guide conduits vary widely in 
terms of their composition, but their most basic function isolates the damaged nerve, 
concentrating neurotrophic signals from the distal stump while eliminating unwanted, scar-
forming immune cell infiltration71.  This cellular isolation must allow constant nutrient exchange 
for the sensitive nerves; these competing concerns have been addressed in recent years by tightly 
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controlling the porosity and thickness of nerve guide conduits71. The wall of these conduits, 
either pre-fabricated tubes or wraps, must be strong enough to retain suture and avoid collapse 
yet soft, flexible, and biocompatible (eliciting little or no immune response) to prevent 
inflammation63. While some nerve guide conduits are made of material that is not intended to 
degrade, such as poly-vinyl alcohol (PVA), silicon, or poly-urethane (PU), work in recent years 
has led to the creation of several commercially-available biodegradable nerve guide conduit 
scaffolds composed of poly-glycoli c acid (PGA), poly-lactic acid (PLA), poly-caprolactone 
(PCL), or some combination of the FDA-approved polymers. These polymer conduit scaffolds 
degrade through hydrolytic bond cleavage at successively slower rates thought to allow gradual 
replacement by native tissue63. 
Because of their solubility in organic solvents, these polymers are also easily manipulated 
into desired shapes, such as aligned fibers created through electrospinning, that provide physical 
guidance and potentially increase the efficiency of extending neurites72. Biologically-derived 
materials like fibrin may also provide this physical link; fibrin composes the natural bridge 
linking two nerve stumps during normal nerve repair, collagen or gelatin (denatured collagen), 
chitosan, keratin, hyaluronic acid, and even silk fibroin have been incorporated into nerve guide 
scaffolds with intriguing results in animal models thought to be due to nerve cell-ECM 
interactions72. Such soft molecules fail to protect nerves from mechanical damage and degrade 
on the order of days, weeks, or, at best, months when therapeutic intervention may be required 
for several months or years51,63,73,74. Hybrid scaffolds may utilize various combinations of 
synthetic and natural biomaterials to precisely tune the degradation rate and ECM signaling 
molecules72. 
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Stem cell or growth factor augmentation of these guides remains a popular topic of 
research. This includes the incorporation of bioactive neurotrophic factors - including NGF, 
BDNF, neurotrophin-3 (NT-3), GDNF, and IGF-1, or Schwann cells/Schwann cell-mimics that 
express these factors69,75–78. Stem cell transplantation may affect these functions through an 
immunomodulatory, paracrine effect. 
1.5 BONE CONSIDERATIONS 
Bone fracture healing is another process that is delicately balanced with active angiogenesis. 
Among the tissues discussed, bone is unique in its potential to heal with virtually no scarring 
when injured in the adult30; however, vascular disruption is associated with delayed or non-union 
of bony fractures. In addition, inflammation plays a role in bone formation or destruction79. 
Extensive in vitro and in vivo work has investigated bone formation over the years, leading to an 
understanding of the necessary gene expression and matrix-production timecourse required for 
proper bone formation and healing. 
 
1.5.1 In vivo osteogenesis during fracture repair 
 
In the adult, bone forms chiefly through endochondral ossification. During endochondral 
ossification, a cartilaginous matrix is deposited, and subsequent remodeling, chondrocyte-
changes including hypertrophy, and, eventually, mineralization produces the mineralized 
collagen structure known as bone. The process is closely associated with vascular remodeling80. 
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In vivo, normal bone repair relies on a dynamic balance between matrix deposition and 
matrix resorption, carried out by the balanced activities of osteoblasts and osteoclasts, 
respectively, among other cell types. Dysregulation of either cell types leads to pathology. 
Osteoclasts, derived from hematopoietic CD34+ precursors, are recruited to the site of 
injury/fracture, and their release of embedded factors following mineral- and collagen-matrix 
degradation signals the beginning of a cycle of bone formation81. They mature in response to 
receptor activator of nuclear kappa-B ligand, among other molecules. Osteoblasts, committed 
matrix- and mineral-producing mesenchymal cells, express genes roughly following the 
timecourse detailed in 82, generated to describe in vitro osteogenesis, with a few exceptions. The 
addition of TGF-β family members bone morphogenetic proteins (BMPs) -2, -4, and -7 to factors 
released during wound healing promoted bone formation and osteoblast maturation83. Although 
it can stimulate mature osteoblasts to maintain their osteogenic phenotype, activin opposes bone 
formation by encouraging the function and maturation of osteoclasts; its actions can be opposed 
by inhibin or follistatin, which are released primarily by the gonads84,85. In addition, Indian 
hedgehog and parathyroid hormone-related peptide as well as their induced factors play strong 
roles in osteogenesis86. 
Within the osteoblasts, runt-related transcription factor-2 (RUNX2) increases, eventually 
driving the expression of osterix, osteocalcin (OCN), and bone sialoprotein-II (BSP), among 
other molecules, which are deposited within the newly-formed collagen-I (COL-I) matrix87. Prior 
to this mature, matrix and mineralizing phenotype, BMP2 signaling is necessary for observed 
increases in production of these matrix-deposited factors, especially in muscle-derived osteoblast 
progenitors87, but excessive amounts can cause pathologies88. Hydroxyapatite minerals 
composed of calcium phosphate are nucleated by both collagen and collagen-associated proteins 
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as the immature, woven bone forms, with the necessary phosphates supplied by osteoblast-
supplied alkaline phosphatase (ALP)-phosphate conversion. These changes are summarized in 
Figure 482. Recent work suggests that ALP gene expression, typically used as a marker of early 
osteogenesis, peaks twice in vivo; it is therefore more appropriately called a later osteogenesis 
markers; additionally, COL-I expression by osteoblasts decreases over time89.  
 
 
 
 
 
 
Figure 4: Canonical osteogenic gene expression in vitro and in vivo; reprinted with 
permission82   
Exogenous BMP-2 accelerates these changes but is not necessary given dexamethasone, ascorbic 
acid, phosphate-supplemented culture. In vivo, recent work examining gene expression more 
closely indicates that RUNX2 gene expression typically follows the pattern observed for OPN; 
additionally, COL-IA1 gene expression decreases nearly constantly throughout the culture 
period. The observed differences are likely due to the selection of primers (and if applicable, 
probes) for gene expression analysis89. 
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1.5.2 In vitro considerations 
 
Canonical in vitro osteogenesis mimics osteoblast function and begins with dexamethasone-
driven decreases in fibroblast/multipotent cell production of IL-690; the loss of this stem-ness 
factor allows the COL-I-producing cells to release increasing amounts of calcium91. This excess 
calcium permits the formation of insoluble hydroxyapatite crystals upon conversion of 
exogenous phosphates by ALP. The crystal deposits serve as nucleation points for more crystal 
deposition, eventually forming visible mineral deposits92; RUNX2 again drives the markers of 
mature osteogenesis93. 
Apparent in vitro osteogenesis is sensitive to a variety of factors. Alkaline phosphatase 
may be expressed and present but inactive; necrotic cells or normal cell debris or excess culture 
phosphate can also nucleate mineralization94,95. While outside the scope of this work, three-
dimensional, particularly pre-mineralized matrices have received a great deal of attention in 
recent years, especially because of their potential utility in healing of bone non-unions; robust 
osteogenic responses were observed when both the bone and the vasculature were considered in 
the construct formation80 although specific cell contributions become difficult to distinguish.  
1.5.3 Osteogenesis and angiogenesis 
Endothelial cell and osteoblast interactions are critical for bone formation in vivo. Connexin 43 
enables direct cell-to-cell contact between the two cell types,  and subsequent work indicated that 
the rate of bone marrow- mesenchymal stem cell mineralization may be directly controlled by 
endothelial cells96. Similarly, osteoclast recruitment, as for neutrophils and macrophages during 
 23 
wound healing, is controlled by the migration of osteoclasts across the thin, endothelial-blood 
vessel membrane80. 
1.5.4 Osteogenesis and inflammation 
Lin, et al., found a dose dependent biphasic response of rat neonatal calvarial cells to IL-1β 
treatment. Short treatments (<48 hours) with IL-1β increased bone nodule formation, but longer 
treatments (>4 days) suppressed it. Doses between 1 pg/ml and 10 ng/ml increased early nodule 
formation and mineralization but ultimately adversely affected total nodule formation97. In 
human MSC cultures, Ferreira, et al., found that MSCs form hydroxyapatite, excessively in the 
presence of IL-1β through the activity of ALP98. Any clinical intervention or implant is likely to 
begin the wound healing process anew, stimulating significant local inflammation, so an 
understanding of the limitations of MSCs within the context of inflammation could contribute to 
more useful, directed wound healing. 
 
1.6 ADULT STEM CELLS IN TISSUE REPAIR 
Stem cells are defined as a self-renewing population of cells whose progeny can be differentiated 
to perform specific functions. Totipotent stem cells, such as the fertilized human egg, can 
generate every tissue of the body; pluripotent and multipotent stem cells are progressively 
restricted in their ability to differentiate into multiple tissue types99. The best characterized 
multipotent cells are mesenchymal stem cells. Their plasticity with respect to differentiation and 
recent clinically-relevant advances in identifying, isolating, and concentrating mesenchymal 
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stem cells100 is extremely exciting in the context of tissue repair. A brief history of the use of 
mesenchymal stem cells with respect to tissue repair is discussed below. 
1.6.1 Ultimate in vivo stem cell sources 
Any discussion of adult, tissue-specific stem cells must acknowledge several competing 
viewpoints. One viewpoint holds that multipotent progenitor cells are ultimately derived from 
the bone marrow. Such cells are mobilized into the blood stream upon systemic release of 
inflammatory or stress factors and home to the site of injury101 following chemotactic gradients 
(stromal derived factor-1 is implicated) 102. Another viewpoint holds that adult stem cells are a 
ubiquitous pericyte-like cell type that can be released by local inflammatory or stress factors; a 
third viewpoint suggests a non-vessel-associated resident stem cell103. Regardless of the ultimate 
origin of these adult multipotent progenitor cells, these multipotent stem cells can act to regulate 
inflammation and, once present in the damaged tissue, are thought to participate in tissue 
healing. Stem cell sourcing has become a topic of great interest in recent years, and military-
specific interest has extended to stem cells derived from allogeneic ocular, neural, cardiac, skin, 
muscle, and mesenchymal sources among others6.  
1.6.2 Defining mesenchymal stem cells 
Following their original discovery and several re-definitions in the 1990s, mesenchymal stem 
cells, without source qualifications, were officially defined in 2006104. Experimentally, 
mesenchymal stem cells are identified first by their ability to adhere to plastic. Next, proliferative 
and differentiable mesenchymal stem cells are identified, at a minimum, by the expression of a 
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combination of surface markers including STRO-1, SB-10, SH3 (cluster of differentiation 
[CD]73) and SH4 antigens as well as Thy-1 (CD90), TGF-β receptor type III endoglin (CD105), 
hyaluronic acid receptor CD44, integrin a1 subunit CD29, activated leukocyte-cell adhesion 
molecules (CD166), and possibly others104. MSCs are negative for the hematopoietic markers, 
CD19/CD79a, CD34, CD45, CD11b/CD14 and human leukocyte antigen (HLA)-DR105. CD73, 
SH4 and STRO-1 antibodies recognize antigens that are present on MSCs and other cells but not 
hematopoietic cells106. The presence of CD75, CD90, and CD105 and absence of hematopoietic 
markers, while not sufficient to fully identify a mesenchymal stem cell, has been suggested by 
the International Society of Cell Therapy as the minimum positive criteria necessary to consider 
a potential cell a mesenchymal stem cell104. Density gradient separation of mononuclear cells 
from blood or minced or digested tissue can help to purify the above population, but it remains a 
challenge to isolate pure and unequivocal mesenchymal stem cells from a mixed cell 
population107. 
1.6.3 Autologous versus allogeneic tissue sourcing 
The immune system bestows on the human body the ability to prevent or suppress pathogen 
infiltration; broadly, inflammation recruits the first line of defensive, innate immune cells while 
continued antigen presence primes the antibody-associated adaptive immune response108. While 
these protective functions are useful to combat pathogens, immune rejection can compromise 
cell- or biomaterial-based therapeutic strategies. Exciting evidence suggests that stem cells 
derived from multiple sources may be privileged when it comes to both types of defense109. 
Mixed lymphocyte reaction studies suggest that mesenchymal stem cells can suppress the 
proliferation of those cells in the presence of a known antigen. Additionally, mesenchymal stem 
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cells normally express only one of two Major Histocompatibility Complex (MHC) molecules 
used by the immune system to recognize foreign cells, as they lack HLA-DR expression unless 
activated by stress110. The combination of these  and other findings has led to the use of 
mesenchymal stem cells in clinical trials that attempt to combat graft-versus-host disease, with 
varying success,109 and  suggests that allogeneic, disease- and activity-screened, stem cells might 
be utilized therapeutically.  
Contrasting this statement, mesenchymal stem cells can express both MHC molecules if 
activated by stress, a likely scenario given the exigencies of the healing tissue environment. 
More recent work suggests that mesenchymal stem cells are therefore immune-evasive, rather 
than immune-privileged111, injecting a note of caution into the use of allogeneic mesenchymal 
stem cells. Even without possible immune rejection, storage and supply of tested mesenchymal 
stem cells is likely to be costly and difficult for combat-associated hospitals. This suggests that 
autologous mesenchymal stem cells would be safer for the patient and easier to implement 
clinically. 
1.6.4  Bone marrow-derived mesenchymal stem cells (MSCs) 
First described by Friedenstein in 1965, bone marrow-derived mesenchymal stem cells 
(MSCs)112 were initially identified for their ability to form bone when transplanted 
heterotopically. Through work by Owen113 and, subsequently, many others, the common origin 
of adipogenic, osteogenic, and chondrogenic cells from bone marrow precursors was 
established114. Subsequent work has found some form of differentiable stem-like cell in nearly 
every tissue of the body115. MSCs are thought to home to sites of injury by following SDF-1 
gradients; once present at the site of injury, MSCs work via paracrine mechanisms to draw in 
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immune cells using IL-1β while dampening the severity of other inflammatory factors through 
IL-10116. They additionally secrete hepatocyte growth factor (HGF), epidermal growth factor 
(EGF), and VEGF that can act to promote the proliferation of resident cells and, depending on 
the context, more or less vascular organization117. A very small number of MSCs will engraft or 
fuse with native cells at the injury site. 
In terms of limb reconstruction, bone marrow are perhaps the ideal candidates to use for 
structural repairs as they were first identified as bone-forming cells112. Their angiogenic 
properties are thought to be positive due to high secretion of VEGF and SDF-1107, although a 
large body of work also examines their anti-angiogenic effects on diseases such as cancer, 
possibly finding action through thrombospondin-1 and VEGFR modulation118. MSCs are 
particularly difficult to isolate, requiring a painful iliac crest isolation from a healthy donor or the 
recovering patient.  
1.6.5 Adipose-derived mesenchymal stem cells (AD-MSCs) 
Although MSCs are described as the clinical and research gold standards, particularly in the area 
of bone formation; effective multipotent cells can be isolated from a growing list of tissue once 
deemed to be surgical waste, including adipose tissue, deciduous teeth (dental pulp), and birth-
associated tissues (umbilical cord and placenta), among others119,120. The isolation methods for 
these tissue are typically less invasive than for MSCs, supporting patient recovery, and 
depending on the application, such surgical waste-derived multipotent cells may be more 
effective, therapeutically, than MSCs121. 
Among these alternatively-sourced stem cells, adipose-derived mesenchymal stem cells 
(AD-MSCs) are the most popular and best characterized, as evidenced by their successful 
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transition from research to clinical use120. AD-MSCs and other microvascular cells are known to 
support nerve growth and regeneration122 as well as EC angiogenic function. Osteogenic 
differentiation of AD-MSCs is less robust than MSCs123, but it is still strong enough to warrant 
clinical trials to aid bone fracture repair124. 
1.6.6 Muscle-derived stem cells 
With regards to source-related properties of previous tissues, a great deal of work has been 
published using human-sourced material that has shown promise for clinical translation. 
Growing evidence suggests that skeletal muscle contains or recruits all cell types necessary for 
limb function125. Satellite cells, a CD34+ muscle-derived multipotent cell distinct from pericytes 
or mesenchymal stem cells, have been noted since the 1950s and have been shown to possess 
adipogenic and osteogenic differentiation abilities126. Additionally, Qu, et al127, identified a 
population of slowly-adhering muscle-derived cells possessing multipotent activities and better 
long-term survival. In subsequent work, osteogenic and, more recently, nerve support were 
explored in mouse models125,128. A CD34+ subset, labeled myo-endothelial or vascular 
endothelial progenitor cells, exhibited marked angiogenic activity129. 
In extensive work in mice, Birbrair identified a population of Tuj1+ (a neuron-specific 
beta tubulin) cells derived from Nestin+ muscle pericytes130. Nestin+ pericytes induced in vitro 
angiogenesis and participated in tumor perfusion131. Again highlighting the close interactions of 
the nervous and vascular systems, this finding also suggests that muscle-derived multipotent 
cells, particularly the mixed populations likely to be present in primary isolates, would support 
both nerve and vascular functions in vivo. 
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Survival and tissue repair takes up the majority of the physical resources of a recovering 
blast-traumatized patient. Additional surgeries to isolate the above stem cell populations would 
likely place an undue, possibly unsustainable, burden on the already-taxed patient.  
1.6.7 Traumatized muscle-derived multipotent progenitor cells 
Within the subset of muscle-derived stem cells, MPCs deserve particular note, given their 
essential role in this dissertation work. It was first noted in 1986 that traumatized muscles secrete 
factors that influence the proliferation of reparative satellite cells132; current work and exercise 
science assert that small injuries and incremental repairs are necessary for ultimate restoration of 
tissue function133. First reported in 2008, MPCs were derived from the second- or third-
debridement of wounds of blast-traumatized soldiers who were treated within 3-7 days of their 
initial blast injury; fat- and fascia-free healthy muscle tissue was obtained from the thin margin 
removed during debridement. In the presence of copious amounts of antibiotics, plastic-adherent 
MPCs were filtered from collagenase type II-digested minced muscles. Initial and subsequent 
work showed that these cells were positive for the stem cell markers and negative for 
hematopoietic, lymphocyte and leukocyte markers, discussed in 4.2.8; additionally, cells were 
positive for CD29, CD44, and CD146, indicating cellular and matrix adhesion molecule surface 
expression as well as endothelial cell markers5.  
In addition to standard adipose and chondrogenic differentiation, these cells were shown 
to be capable of osteogenic differentiation, suggesting similarity in function and multipotency to 
MSCs. Because of interest in their contribution to HO, extensive in vitro characterization has 
been carried out. To summarize the work presented in several papers: Total ALP production was 
similar between MPCs and MSCs, but normalized (per-cell) ALP activity was lower in MPC 
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cultures by day 14. Osteogenic MPCs expressed RUNX2, ALP, and OCN differentially from 
growth cultures. MPC culture mineralization began at 21 days and grew stronger after 28 days, 
but this mineralization was moderate when compared to MSCs5,134. EPCs make up an abundant 
fraction of the cells isolated from muscle immediately following digestion and have been 
implicated as the key initiators of FOP, a slow-onset, genetic form of HO17,135. These EPCs 
secrete TGF-β1-3 at detectable levels135,136 which may further enhance or suppress the observed 
osteogenesis in vitro depending on their concentration, duration of activity, and affected 
cells89,137,138. MPCs were shown to express genes for inflammatory markers that affect cell 
differentiation, including IL-1β and IL-6, but this expression was not statistically significant 
from non-traumatized controls or MSCs135,139. Critically, for this work, MPCs were demonstrated 
to express and produce VEGF at similar levels to MSCs139. Later work found key increases in 
BMP6 expression by MPCs derived from patients who developed HO over those who did not136.  
For neurotrophic differentiation, MPCs, were shown to transdifferentiate across lineages 
to a neuroglial-like phenotype; this phenotype proved as adept as MSCs at promoting the growth 
of peripheral nerves on tissue culture plastic140. MPCs expressed and produced BDNF and 
Nestin, markers of neurotrophic and neural activity, respectively, under a specialized 
neurotrophic induction protocol141. Induced cells also displayed increased CD56 presentation, a 
molecule important for MPC-nerve cell interactions141.  
1.6.8 Key differences between MSCs and MPCs 
MPC differentiation along the adipogenic-osteogenic axis was dependent on activin-A which 
MPCs produced preferentially to MSCs in addition to lower follistatin (an inhibitor of activin-
A)142, suggesting a weighting towards an osteogenic phenotype. Peroxisome proliferator-
 31 
activated receptor (PPAR)-γ, an indicator for adipogenesis, was differentially upregulated in 
MPC osteogenic culture compared to MSC. Subsequent work examining HO nodules noted the 
presence of brown- and white-fat markers and the ability of distinct MPC subpopulations, with 
high endothelial marker expression, to preferentially differentiate along an adipogenic 
pathway5,143. Although no mechanism for the difference was investigated, MPC-suppression of 
mixed lymphocyte proliferation, an indicator of MPC immunocompatibility, was less potent than 
that of other types of multipotent stem cells including MSCs139.   
When compared with normal non-traumatized muscle, MPCs express higher ratios of 
TGF-β3 to TGF-β1, indicating a fibrotic/matrix-producing phenotype15. BMP11 and BMP4, 
associated with bone/muscle and bone/cartilage differentiation, respectively, were upregulated, 
while BMP3B, NODAL, and myostatin, associated with DNA methylation, embryonic 
development, and muscle differentiation, were downregulated89,135,144. In one study examining 
osteogenic genes by PCRArray, MPCs expressed higher amounts of RUNX2 but lower ALP and 
OCN than MSCs when each was normalized to their respective growth controls134. Taken 
together, these differences suggest a cell population primed to form either osteogenic or fibrotic 
tissue. The ultimate fate of MPCs likely depends on their environment, a dependence that will be 
explored in the work described below. 
 
1.7 HYPOTHESIS AND SPECIFIC AIMS 
Ongoing research suggests that inflammation alters the ability of cells to respond to their 
environment, sensitizing them to some signals and dampening the influence of others145. Because 
of the inflamed nature of their environment just prior to isolation, MPCs represent a uniquely 
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stimulated cell source. Although frequently compared to MSCs in terms of activity, extensive 
work has gone into characterizing the regenerative potential of MPCs and noted key differences 
between MPCs and MSCs. These differences are likely critical in regulating their biological 
activities under the abnormal or pathophysiological conditions seen in a traumatic wound, and 
further investigation of these differences could expand the potential pathological or therapeutic 
implications for MPCs. To date, no detailed studies have examined MPC activities, either 
pathologic or therapeutic, in the context of their altered isolation/implantation environment or of 
paracrine signaling. 
The overall hypothesis is that MPCs possess regeneration- and clinically-relevant trophic 
and -functional activities capable of influencing angiogenesis, neurite extension, and 
osteogenesis, and that these activities are altered by the physical and cellular microenvironment 
of the MPCs. The following specific aims were designed to test this hypothesis.  
 
 Specific Aim 1: Determine the ability of MPCs to promote angiogenesis by examining 
MPC-influenced EC-organization in vitro and MPC-recruitment of capillaries to an implantable 
construct in vivo. 
Specific Aim 2: Examine alterations in MPC neurotrophic activity due to EC-influence 
and structured biomaterial scaffolds. 
Specific Aim 3: Determine the regulatory effect of IL-1β-simulated inflammation and 
EC-influence on MPC osteogenic differentiation.  
The following chapters detail the results of each specific aim. 
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2.0  TRAUMATIZED MUSCLE-DERIVED MULTIPOTENT PROGENITOR CELLS 
RECRUIT CAPILLARIES AND STIMULATE ANGIOGENESIS THROUGH 
VASCULAR ENDOTHELIAL GROWTH FACTOR-A ACTION 
2.1 INTRODUCTION 
Along with a critical supply of nutrients, capillary networks composed of microvascular 
endothelial cells (ECs) allow the invasion of various blood-delivered immune and multipotent 
cells, possibly bone marrow-derived mesenchymal stem cells (MSCs), that can augment the 
muscular, osteogenic, and neural functions of the healing limb6,146. Additionally, capillary 
networks are thought to be maintained or disrupted through the interactions between ECs and 
resident, vessel-associated MSCs/pericytes147. 
Normal vascular function of ECs is influenced by a variety of external and internal 
factors that exquisitely balance opposing signals promoting vessel sprouting and vessel 
regression31. One such molecule is vascular endothelial growth factor (VEGF), which has been 
effective at helping patients in the clinic to recover from ischemic coronary episodes148. VEGF 
acts synergistically with platelet-derived growth factor (PDGF), fibroblast growth factor (FGF), 
and angiopoietin (ANGPT) in various models to enhance collateral vessel development149–151. On 
a cellular level, VEGF is critical to EC survival and maintenance of normal vessel function152,153, 
and in tip cell EC sub-populations, VEGF increases cell motility, proliferation, and migration154. 
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When cultured under various conditions in vitro, MSCs have been consistently reported 
to secrete VEGF, among several other factors that can tip the balance towards sprouting 
angiogenesis. Present in detectable levels within MSC-conditioned medium (CM), these other 
factors include: angiogenin, ANGPT-1 and -2, chemokine (C-C) ligand (CCL)-2, chemokine (C-
X-C) ligand (CXCL)-7, FGF, hepatocyte growth factor (HGF), insulin-like growth factor (IGF)-
1, interleukin (IL)-6, nitric oxide (NO), PDGF, stromal-derived factor (SDF)-1, and tissue 
inhibitor of metalloproteinase (TIMP)-1 and -2155–160. Among these, MSC-produced VEGF and 
FGF appear to be the most potent angiogenic molecules present in MSC-CM; their combined 
activities can account for up to two-thirds of observed MSC-CM support of EC proliferation and 
migration161. VEGF alone may constitute up to half of the total MSC-CM support of EC network 
organization162.  
Recent work has demonstrated the production of VEGF by MPCs and the positive effect 
of MPC-CM on EC proliferation139. As a first step towards assessing the potential and viability 
of MPC-based therapies, the study reported here attempted to address the effect of MPCs, 
compared to MSCs, on angiogenesis. Two angiogenesis assay platforms were utilized to test the 
effect of MPC secretome, focusing on VEGF, based on the ability of ECs to form branched 
networks with one another in vitro and the chemotactic effect and the recruitment activity of 
MPCs on capillaries in vivo.  
Results presented below showed that, in a Matrigel EC cord-forming assay38, conditioned 
medium derived from MPCs (MPC-CM) was pro-angiogenic through the activity of VEGF.  
MPCs also recruited small-caliber blood vessels in the chick embryonic choriollantoic membrane 
(CAM) in vivo, in a manner dependent on cell density and other factors besides VEGF. Taken 
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together, these findings support the potential therapeutic value of MPCs for the promotion of 
angiogenesis and also illustrate biological differences between MPCs and MSCs. 
2.2 METHODS 
2.2.1 MPC isolation 
MPCs were harvested from human muscle tissue specimens obtained following debridement of 
blast-traumatized wounded US military personnel with Institutional Review Board (IRB) 
approval (Walter Reed National Military Medical Center). Fascia-free minced muscle tissue (200 
µg) was enzymatically digested for 2 hours (Dulbecco’s Modified Eagle’s Medium, DMEM; 
GIBCO; 0.5 mg/ml collagenase 2, Sigma) at 37°C under gentle agitation, as originally described 
by Jackson, et al163. MPCs were strained through a 40 µm cell strainer and pelleted by 
centrifugation at 200 x g for 5 minutes. Cells were resuspended in DMEM, 10% fetal bovine 
serum (FBS; GIBCO), and 5% penicillin-streptomycin (PS; GIBCO), plated in a T150 tissue 
culture flask (Corning), and allowed to adhere overnight. Cells were then washed extensively 
with phosphate-buffered saline (PBS; GIBCO) and cultured in DMEM, 10%FBS, and 3% 
antibiotics-antimycotic (PSF: penicillin-streptomycin-Fungizone; GIBCO), at 37°C under 5% 
CO2 until confluent.  
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2.2.2 MSC isolation 
Bone marrow-derived MSCs were obtained after flushing scissor-minced trabecular bone 
removed from the femoral heads of patients undergoing total hip arthroplasty (IRB approval, 
University of Washington). The cell-enriched rinsing medium (α-Minimal Eagle’s Medium, α- 
MEM; GIBCO; 1% PSF) was strained through a 40 µm cell strainer, and the resulting cells 
pelleted at 300 x g for 5 minutes. Cells were washed with rinsing medium and pelleted twice 
before re-suspension in growth medium (rinsing medium + 10% FBS + 1 ng/ml FGF-2; Fisher). 
Cells were allowed to adhere to T150 flasks and cultured in growth medium at 37°C under 5% 
CO2 until confluent. 
2.2.3 Culture expansion 
At confluence, cells were trypsinized and either frozen at 1 x 106 cells/ml in Freezing Medium 
(Invitrogen) or passaged using growth medium at 1 x 106 cells/T150 flask. MSCs (n=4; mean 
age, 41±24 years, equal male vs. female, with confirmed colony-forming abilities and tri-lineage 
differentiation potential164, Appendix A) were utilized at passage 3-5. MPCs (n=4; mean age of 
24±4 years, all male, Appendix A) were utilized at passage 5-8. Human foreskin fibroblasts 
(HFFs), obtained as a cell line (Lonza), were seeded from frozen vials at 1 x 106 cells/T150 tissue 
culture flask and passaged as above and utilized at passage 6-10. Human dermal ECs were 
obtained from the Centers for Disease Control and Prevention with Material Transfer 
Agreement, and cultured with EGM-2MV Bulletkit (Lonza), passaged or frozen as above, and 
utilized at passage 8-10. 
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2.2.4 Conditioned medium generation from monolayer cell cultures 
Upon reaching ~90% confluence, cells were passaged to a new density of 1 x 104 cells/cm2 in 
growth medium. After 24 hours, cells were washed once each with PBS and Hank’s Balanced 
Salt Solution (HBSS, GIBCO), and cultured for 72 hours in 0.24 ml/cm2 basal medium (DMEM, 
1% insulin-transferrin-selenium-X [ITS-X], 2% PSF). Non-cell conditioned control CM was 
generated by incubating basal medium in empty flasks. All CM samples were centrifuged at 200 
x g for 5 minutes and the supernatant frozen at -20°C for later use. At the time of use, CM 
samples were thawed and again centrifuged at 200 x g for 5 minutes before use in culture. To 
determine the relative amount of protein produced per cell, CM was concentrated 20x using 
Amicon Ultra-4 centrifugal concentrator columns (3kDa cut-off, Millipore). CM protein content 
was determined using a BCA Protein Assay (Pierce) and bovine serum albumin standard curve. 
2.2.5 siRNA silencing of VEGF 
MPCs and MSCs were seeded at 2 x 104 cells/cm2 in 6-well plates (Costar). After 24 hours, 
VEGF gene expression was targeted for silencing with SMARTpool silencing (si)RNA and 
Dharmafect1 (Dharmacon) according to the manufacturer’s instructions. After an overnight 
transfection, cells were washed and incubated in FGF-2-free growth medium for 24 hours. This 
wash procedure was repeated 48 hours post-transfection, and transfected cells were utilized for 
subsequent experiments beginning 72 hours post-transfection.  
Following transfection and washes, cells were lysed with RLT buffer (Qiagen). After 
RNA was isolated and converted to cDNA (Superscript III: Invitrogen), VEGF165 and β-actin 
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primers (Qiagen, proprietary sequences) were utilized for qPCR gene expression analysis (SYBR 
Green: Invitrogen) on AB Hit9000 (AB). 
For CM collection, seventy-two hours post-transfection cells were washed in PBS and 
HBSS and 3 ml of basal medium were added, followed by additional culture for 48 hours. The 
collected CM aliquots were kept frozen at -20°C until analysis by sandwich ELISA against 
human VEGF, PDGF, FGF2, and IL-1β (R&D). 
2.2.6 In vitro angiogenesis: cord formation assay preparation, CM addition and cord 
maturation 
Cord-forming surfaces were prepared by spreading 10 µl ice-cold growth factor-reduced 
Matrigel (BD)/cm2 onto 96-well non-tissue culture treated plates (Costar; ibidi). Matrigel was 
allowed to gel at 37°C for 1 hour, followed by the addition of 100 µl basal medium to the wells. 
After an additional hour, 90 µl of basal medium was removed from each prepared Matrigel-
containing well. 2 x 104 ECs in 20 µl basal medium were seeded in each well, and allowed to 
adhere to Matrigel undisturbed for 1 hour. 
A 200 µl aliquot of CM was added to each well. EC cultures were incubated overnight 
for 16 hours, washed in PBS, and fixed in 2% paraformaldehyde. Bright-field mosaic images of 
connected cords formed in each well were obtained at 40X magnification using an inverted 
microscope (Olympus IX81) with automated stage, controlled by Metamorph software. Multiple 
images (>40) from each well were batch processed with a custom macro to allow analysis with 
Angiogenesis Analyzer165 (Fiji/ImageJ). False counts due to clustered cells or contrast created by 
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well curvature were excluded. Network length and extent of branching per microscope field were 
compared for all groups. 
2.2.7 MPC/MSC/HFF live cell encapsulation in constructs 
At ~90% confluence, cells were trypsinized, pelleted, and resuspended in visible light-activated 
(photoinitiator: 0.1% lithium phenyl-2,4,6-trimethylbenzoylphosphinate) 10% (w/v) 
methacrylated-gelatin, as described recently166. Ten µl of gel were placed on a marked, 5 mm 
round glass coverslip, and visible light applied for 5 minutes using a commercial illuminator 
(LEDwholesalers; 450 nm) to create uniform-sized constructs. Pellets were washed to remove 
the photo-initiator and stored briefly in Phenol Red-free DMEM before placement on CAM or in 
culture in vitro. 
2.2.8 Cell proliferation in cell-seeded constructs and collection of conditioned medium 
Constructs were cultured in Phenol Red-free DMEM (1 ml/6 constructs) for up to 48 hours. CM 
from constructs was collected daily and analyzed for angiogenic factors by ELISA, as described 
above. Construct cell density and viability were assessed by Live-Dead staining (Invitrogen); 
live and dead cells occupying arbitrarily selected space within the construct volume were 
quantified using a custom NIH ImageJ macro.  
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2.2.9 CAM angiogenesis 
Induction of vessel recruitment in vivo was assessed with the CAM assay, using chick embryos 
in shell-less culture167.   Three to six cell-seeded constructs were distributed, 2-3 cm apart, on the 
surface of each CAM of incubation day 9 chick embryos. After 48 hours, small (<40 µm) blood 
vessel invasion into the construct was imaged (SZX10 Olympus) and counted by a blinded 
observer. Constructs were then excised from the CAM, and the number of live cells quantified as 
described above. 
2.2.10 Statistical analysis 
At least three independent experiments with at least three replicates per condition were 
performed for each assay. Outliers were removed with Grubbs’ test. All data were presented as 
mean + standard deviation (SD). Significance was determined by Student’s t-test (n=3) and one- 
or two-way ANOVA (n>3), as appropriate, with Tukey’s post-hoc analysis (GraphPad Prism). 
2.3 RESULTS 
2.3.1 MPC effects on EC cord formation in vitro: VEGF involvement 
To determine if MPCs contribute, ultimately to blood vessel recruitment, the effect of MPC-CM 
on EC cord network complexity was assessed. Because MPC-produced VEGF might play a maor 
role MPC-associated vessel recruitment, MPC- and (control) MSC- VEGF was removed by 
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siRNA silencing. After confirming that VEGF was effectively silenced, the effect of MPC- and 
MSC- produced-VEGF on EC network complexity could be determined. 
 MPCs and MSCs were tested for their ability to influence the cord-forming abilities of 
Matrigel-plated ECs (Figure 5). Only CM generated by MPCs positively influenced the 
complexity and length of EC networks relative to control (non-cell-conditioned) CM. VEGF 
production in MPCs and MSCs was efficiently silenced using SmartPOOL siRNA. Decreases in 
VEGF gene expression were observed, and CM from gene specific siRNA treated populations 
contained significantly lower levels of VEGF than control cultures (Figure 6). Interestingly, 
silencing of VEGF significantly affected the ability of MPCs to stabilize EC networks, but 
silencing did not appear to affect the angiogenic activities of MSCs (Figure 7). MPC support of 
EC network formation is particularly impressive given the small but significant difference in 
measured protein concentrations between the pooled CMs (MPC-CM 2.8 ± 0.5 mg/ml, MSC-CM 
3.8 ± 0.7 mg/ml, p<0.05). 
 
 
 
Figure 5: Representative images of EC networks seen in vitro    
Networks were formed during 16-hour exposure to (A) cell-free control CM, (B) MSC-CM, and 
(C) MPC-CM. MPC-CM encouraged the creation of longer and more complex EC networks. 
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Figure 6: VEGF silencing by siRNA successfully decreased secreted VEGF concentrations 
Treatment with sequence-specific VEGF siRNA significantly reduced VEGF concentrations in 
CM of both MPC and MSC. * p<0.01, n=6. 
 
 
 
 
Figure 7: Effect of CM from VEGF-silenced MPCs and MSCs on the organization of EC 
cord networks, assessed based on (A) EC tube branching, and (B) EC networking  
MPC-CM enhanced the cord-forming ability of ECs, and that support was significantly 
decreased by VEGF silencing; MSC-CM did not significantly affect EC cord-forming abilities 
regardless of VEGF content.. n=3, **p<0.01. 
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2.3.2 MPC hydrogel construct 
The ability of MPCs and MSCs to enhance EC cord formation prompted examination of 
their pro-angiogenic activities in vivo when delivered in cell-seeded scaffold constructs, as a first 
step to evaluate the therapeutic potential of autologous cell implantation. For such an application, 
a crucial requirement here was the long-term viability of the seeded cells within the scaffold 
construct. A photocrosslinked gelatin-based hydrogel recently developed in our laboratory, 
which exhibited excellent cell retention and compatibility properties168,169, was therefore used to 
encapsulate MPCs and MSCs. For this study, MPCs or MSCs were seeded in 10 µl 
photocrosslinked methacrylated-gelatin at various densities (10 x 103, 50 x 103, and 100 x 103 
cells per construct, designated as 10k, 50k, and 100k, respectively). MPC and MSC cell number 
and viability at 24 and 48 hours after encapsulation were determined by automated cell counting 
of flattened vertical stacks of Live-Dead stained cells (Figure 8). Given culture under serum-free 
conditions, both MPCs and MSCs exhibited reasonably high viability (>60%), and cell number 
did not change significantly for any group over the course of the observation, implying neither 
pronounced cell death nor proliferation. Very few cells were observed to have migrated from the 
constructs onto the surrounding tissue culture plastic. 
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Figure 8: Encapsulation of MSCs and MPCs within photo-crossslinked methacrylated-
gelatin constructs  
(A) Ten μl photo-crossslinked methacrylated-gelatin constructs encapsulating (B) 10k, (C) 50k, 
and (D) 100k cells per construct. Scale bars as indicated.  Viability (E) and number (F) of 
encapsulated cells determined by Live-Dead staining.  Stained cells were imaged in vertical 
stacks that were processed and used to determine construct viability and abundance after 24 and 
48 hours in serum-free DMEM. Cell viability remained high (>60%) with no evidence of marked 
cell death or proliferation without regard to cell type or days in culture. n≥3, **p< 0.01 due to 
cell loading differences at the same timepoint and loading density. n.s.s. = not statistically 
significant. 
 
2.3.3 Cytokine release from constructs 
Because hydrogels are often used to sustain the release of therapeutic growth factors in vivo74, it 
was important to assess the level of growth factors secreted by the cells into the conditioned 
medium. CM generated in the above serum-free experiment was collected and assayed for the 
presence of VEGF, showing time-dependent release profiles (Figure 9). Initial experiment also 
 45 
showed that FGF-2 was detected at ~100 pg/ml in CM derived from two MPC and one MSC 
patients, but subsequent results were variable. PDGF and IL-1β were not detected in the CM. As 
a positive control, cell-free constructs encapsulating only the tested growth factors released 
>80% of the encapsulated growth factor after 24 hours (Appendix B), implying minimal 
retention of cell-secreted growth factors by the biomaterial scaffold. 
 
 
 
Figure 9: Production and release of VEGF by (A) MPCs and (B) MSCs encapsulated in 
photo-crosslinked constructs  
VEGF was produced as a function of initial cell seeding density with 50k initial cells/construct 
as the most efficient. The results showed MPC-VEGF production was unaffected by time in 
culture, in contrast to MSCs.  n=3; *p<0.05, **p<0.01. n.s.s. = not statistically significant. 
 
2.3.4 In vivo angiogeneic activity of cell-seeded constructs using the CAM assay 
Forty-eight hours after the MPC- and MSC-encapsulated gelatin constructs were placed 
on the CAM surface, the number of capillaries recruited to the construct was quantified by a 
blinded observer (Figure 10A-E). The results clearly showed the pro-angiogenic activity of both 
MPCs and MSCs, with the former being more potent, particularly at higher cell seeding density.  
In comparison, a control cell type, the HFFs, was completely inactive at all seeding densities. 
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The potential involvement of VEGF in mediating capillary recruitment was also investigated in 
the CAM system by utilizing the VEGF-silenced cells described earlier (Figure 6), seeded at 50k 
cells/construct (n=2); however, no significant differences in capillary recruitment were apparent 
between treatment group or cell type (Figure 11), possibly due to excessive endogenous CAM 
VEGF production. Experiments with adult animals might show heightened VEGF 
responsiveness. 
After 48 hours, constructs were removed from the CAM, and viable cells within the 
construct were quantified with Live-Dead assay as described above (Figure 8).  Cell-free 
constructs were similarly examined to correct for non-specific cell migration from the chick 
CAM, and the maximum number of adherent/invasive cells subtracted from the reported values 
(typically on the order of 10-100 adherent cells per construct). The results showed that, as was 
the case for constructs maintained in vitro (Figure 10F), significant maintenance of viable cells, 
including at the highest density of 100k. This finding suggested that MPCs implanted in a 
hydrogel construct could remain viable and active for longer durations and that additional testing 
using this approach of MPC-based therapy should be applicable in larger animal models and for 
longer duration. 
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Figure 10: In vivo CAM assay of pro-angiogenic activity of MPCs   
Cells (MPCs, MSCs, and HFFs) were encapsulated in photocrosslinked gelatin hydrogel, and the 
constructs placed on day-9 chick embryonic CAM. Forty eight hours after implantation, 
angiogenic induction in (A) cell-free control, (B) MPC, (C) MSC, and (D) HFF groups was 
assessed by counting the (E) number of CAM capillaries recruited to each construct using 
contrast-enhanced dissecting microscope images; n≥8, **p<0.01. Black marks near the center of 
each coverslip (A-D) allowed easy identification of constructs on the CAM surface. Small 
vessels, denoted by red circles, were counted if they appeared to cross the edge of the 5mm 
diameter coverslip (A-D). Representative images for each encapsulated cell type (B-D) at an 
initial seeding density of 50k cells/construct were shown. (F) Encapsulated cell viability was 
assessed via Live-Dead staining; n≥ 3, *p<0.05, **p<0.01. MPCs recruited significantly more 
vessels than any other cell type, and despite fewer surviving encapsulated cells by 48 hours, 
MPCs recruited blood vessels more efficiently than any other cell type at an initial cell density of 
50k cells/construct. 
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Figure 11: In vivo CAM assay of pro-angiogenic activity of VEGF-silenced MPCs and 
MSCs   
The number of CAM vessels recruited by VEGF silenced MPCs and MSCs was not significantly 
different from control groups, indicating that exogenous VEGF in the context of embryonic 
vessel recruitment is insufficient to markedly alter capillary recruitment; n = 3. 
 
2.4 DISCUSSION AND CONCLUSIONS 
The present work confirmed gene expression-regulated production of VEGF (Figure 6) 
by MPCs and MSCs via sandwich ELISA analysis of CM, while production of IL-1β, FGF-2, 
and PDGF by both cell types was inconsistent or undetectable. The MPC secretome was 
observed to have a net positive effect on the organization of EC cords in vitro, and this effect 
was abrogated by siRNA silencing of VEGF. MSC-secreted VEGF did not alter the net-zero 
effect of MSC-CM on EC microvascular network length and extent of branching (Figure 7). To 
test the suitability of MPCs for use in vivo, MPCs were encapsulated and cultured in vitro within 
a mechanically-tunable, photocrosslinked hydrogel scaffold169 (Figure 8). A majority of the 
encapsulated MPCs survived and continued to produce VEGF, and while MSCs tolerated 
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encapsulation, MSC-VEGF production declined over time (Figure 9). After two days on the 
surface of the CAM, most encapsulated cells were still viable and relatively few CAM cells had 
migrated into each construct. Consistent with the in vitro assays, MPCs exhibited more efficient 
capillary recruitment abilities than MSCs (Figure 10), but that activity was no longer VEGF 
dependent. Non-specific cell- or hydrogel-mediated CAM inflammation was ruled out due to the 
observed lack of CAM response to encapsulated HFFs and normalization to cell-free control.  
VEGF is a potent and highly-expressed angiogenic molecule that acts to affect 
endothelial cell migration, proliferation, and tube formation, among other functions49. When 
coordinated with other molecules, VEGF-associated EC function changes result in angiogenesis, 
the formation of new vessels as extensions of existing vasculature. Besides VEGF, serum-starved 
or otherwise-activated MSCs produce a host of molecules that can modify or mask the effect of 
VEGF on angiogenesis and wound healing, including ANGPT-1, FGF-2, IGF-1, HGF, SDF-1, 
and PDGF147,151,156,170, that variously increase EC proliferation, migration, branching, and/or 
adhesion. Additionally, cytokines that affect both endothelial cells and surrounding inflammatory 
cells, including CCL-2, IL-1β, and IL-6 can aid in the loosening of EC-EC connections, allowing 
EC tip cells to sprout and form nascent blood vessels90,155,171,172. However, MSC-secreted 
molecules are not purely pro-angiogenic. Anti-angiogenic activity in MSCs has been observed to 
be mediated through several routes, including through soluble, decoy forms of growth factor 
receptors such as soluble PDGF receptor173, soluble VEGF receptors (sVEGFR-1 and sVEGFR-
2)35 and through exosomes/microparticles isolated from MSC-CM, some of which contain 
VEGF-inhibiting microRNA174–176. While less thoroughly-characterized than MSCs, several of 
the above-mentioned pro-angiogenic factors are known to be expressed or produced by MPCs. 
Similar gene expression levels for IL-1β, IL-6, VEGF, and FGF-2 were observed between MPCs 
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and MSCs139. Comparative CM analysis could elucidate interesting differences that might 
explain the observed differences in EC support activities between MPCs and MSCs.  
One well-established in vitro model for angiogenesis involves the seeding of ECs on 
growth factor-reduced Matrigel or similar laminin-rich substrate and observing EC network 
characteristics; the cord-forming assay as it was implemented in this work allowed a complete 
description of EC networks formed within an entire well.  Other in vitro angiogenesis models 
required manual selection of imaging areas (3D tubule assay), leading to possible experimental 
bias, or assayed the response of improperly sourced (fetal- or aortic-) endothelial cells177. EC 
cord-networks are extremely dynamic, maintaining highly-branched multi-cellular configurations 
under the influence of pro-angiogenic factors and regressing to relatively inert cell clusters 
within a few hours following the removal of pro-angiogenic factors. Because the ECs used here 
were derived from a stably-transformed microvascular cell line178, and cord-formation versus 
physiologically functional vascular tube formation was assessed, it is possible that the pro-
angiogenic effects of MPCs observed in vitro will not transfer to an in vivo setting. 
To relate in vitro and in vivo settings, various in vivo angiogenesis models exist; however, 
each in vivo model comes with its own limitations. Of high priority is the cost to both the 
researcher and animal, as an entire, possibly immunocompromised animal must be bred, housed 
safely for the duration of the experiment, and sacrificed to allow analysis of a relatively small 
tested area (rat or mouse skin pocket, windowed rabbit ear, or corneal micropocket)177. Although 
limited to the short time period of embryonic development, the shell-less chick CAM assay 
offers the advantage of a relatively large and easily-imaged angiogenic surface, allowing for up 
to six assays per embryo, and several dozen assays can be housed in a standard static incubator. 
The relatively short assay, occurring over a matter of days, minimizes any suffering of the 
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developing embryo, but appropriate controls must be utilized on every CAM as local tissue 
inflammatory responses are highly variable from embryo to embryo. While the argument can be 
made that observations of avian and human cell interactions are not likely to be relevant to 
human wound healing, the widely-used CAM assay offers a useful and relatively inexpensive 
screening tool to identify populations of broadly pro-angiogenic cells, or specific factors 
produced by cells, that have a high likelihood of promoting angiogenesis in vivo. With the CAM 
assay, we observed marked vessel recruitment by MPCs with significant and strong recruitment 
at median cell density. Work is currently underway to confirm MPC therapeutic activities in a 
mammalian system. 
Given some reports on the high dependence of MSC-angiogenic activity on VEGF, as 
presented in the introduction162, our finding of minimal pro-angiogenesis by MSCs should be 
considered in view of a recent study on the source-related differences in MSC angiogenic 
function, which showed similar, underwhelming bone marrow-derived MSC support of in vitro 
angiogenesis when compared to adipose-derived MSCs179. This cell source-related difference in 
angiogenic potential both in vitro and in vivo could be related to different mechanisms utilized 
by each cell type to promote angiogenesis, as has been reported for adipose-derived versus bone 
marrow MSCs180,181. Future work analyzing and comparing the secretomes and matrix 
interactions of MPCs and variously-sourced MSCs is critical in determining specific applications 
where MPCs might better meet therapeutic challenges than clinically-available MSCs.  
A few caveats can be applied to the above conclusions. As has been identified in previous 
studies, the MPCs studied here were derived from a fairly homogeneous young, male donor 
population compared to the older, mixed gender MSC donor population. Given comparable 
VEGF production and proliferation rates between the two populations, it is unlikely that age-
 52 
related changes account for the observed differences123. Additionally, this work has presented 
ECs and the capillaries that they form as relatively passive interpreters of MPC- or MSC-
angiogenic signals; in reality, ECs themselves can regulate angiogenesis via several mechanisms, 
such as altered Tie-2 expression and/or ANGPT-2 release154,182. The nature and regulation of 
interactions between ECs and MPCs must be elucidated to better manipulate the ultimate 
therapeutic potential of MPCs. 
Taken together, these findings suggest that MPCs preferentially promote angiogenesis in 
a manner distinct from and possibly superior to MSCs. This effect is likely due to a combination 
of MPC-secreted VEGF activity on ECs and other, possibly matrix-modifying factors183,184, 
affecting endothelial, endothelial cell-associated, or immune cell activities. MPCs are therefore 
likely to be useful in the recruitment and stabilization of vasculature necessary to support an 
implanted construct. The significant advantage of their easy isolation and autologous sourcing 
further lends itself to the potential therapeutic use of MPCs. If encapsulated within a degradable 
hydrogel, viable and autologous MPCs could conceivably be used to procedures that require 
enhanced vascular support, including soft tissue or bone reconstruction in blast-traumatized 
limbs. 
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3.0   NEUROTROPHIC SUPPORT BY MPC AND EC: A ROLE FOR VEGF? 
3.1 INTRODUCTION 
The capacity for nerve regeneration after injury is related to the mechanism of injury and the 
time to treatment. While autograft nerve and blood vessel transplantation are the clinical 
treatments of choice, donation sites of appropriate size are limited and require a second surgery, 
damaging the otherwise healthy tissue of an already taxed patient. Severely-injured patients can 
be treated with synthetic, biodegradable nerve guides as a last resort, but such guides are 
associated with less favorable outcomes51.  
The most sophisticated nerve guide conduits attempt to mimic the physical, chemical, and 
temporal aspects of the native repair processes. For synthetic guide-scaffolds, substrate 
patterning or the incorporation of aligned fibers mimic bands of Büngner formed by proliferating 
Schwann cells185,186. Advancements in polymer chemistry and refinements of electrospinning 
technique allow the precise control of the fiber diameter, alignment, and degradation rate 187,188 
with the ultimate goal of complete scaffold replacement by native tissue. Poly-caprolactone 
(PCL) is a biodegradable synthetic polymer that can be easily electrospun; the in vivo 
degradation rate is comparable to the rate of native tissue replacement76. Additionally, PCL 
nerve guide conduits are clinically-approved, lowering the potential regulatory barriers to use60. 
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In addition to physical guidance, the maintenance of Schwann cell-secreted neurotrophic 
factors is important for motor and sensory nerve survival and extension towards the target 
tissue67. These secreted factors include, but are not limited to, nerve growth factor (NGF), brain-
derived neurotrophic factor (BDNF), ciliary neurotrophic factor (CNTF), and glial cell derived 
neurotrophic factor (GDNF), and they can be tethered to or encapsulated within the nerve guide 
conduits for controlled release65,186,189.  
The bioactivity of exogenously-delivered factors may degrade with time, and 
experiments have shown that direct transplantation of dynamically-responsive cellular growth 
factor sources, such as Schwann cells and Schwann cell-like bone marrow-derived mesenchymal 
stem cells (MSCs), can enhance nerve repair outcomes190,191. Nerve co-culture with or treatment 
with conditioned medium derived from Schwann cells, Schwann like-MSCs, or undifferentiated 
MSCs positively influenced the length and density of neurons dissociated from embryonic dorsal 
root ganglia (DRG) 192,193. 
In addition to stimulating the damaged nerve, MSCs are thought to signal the surrounding 
support tissue and (possibly) invading immune cells; the net result of MSC activity is a positive 
effect on nerve defect healing157,194. The use of allogeneic MSCs, while clinically approved for 
certain therapies, face intensifying scrutiny over their immunogenicity111. Currently, the sourcing 
of autologous MSCs, even the minimal procedure required for adipose-derived MSCs, also 
involves invasive procedures. 
Recent studies have shown that surgical waste, obtained following standard debridement 
of traumatic extremity injuries, yields a population of blast-traumatzied muscle-derived 
multipotent progenitor cells (MPCs) 5; MPCs are poised to be ideal candidates for nerve repair.  
MPC activities are similar to those of widely-known and clinically-utilized bone marrow-derived 
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MSCs163. MPCs express NGF, BDNF, CNTF, and neurotrophin(NT)-3141. MPC culture in a 
defined medium for neurotrophic induction enhances the expression of these factors141 and 
stimulates neurite outgrowth in embryonic dorsal root ganglia 140. MPCs also exhibit the ability 
to control their local proteolytic microenvironment 160, suggesting that MPCs might also 
contribute neurotrophic benefits through indirect means. 
Vascular cells, particularly endothelial cells, are intimately connected with the 
development, growth, and continued health of nerves191, often utilizing similar molecular 
pathways for physical guidance29. MSCs are associated with endothelial cells and may interact 
with them in the maintenance of the stem cell niche and in endogenous regenerative 
processes105,183,184. There is increasing evidence that the endothelial cell ligands vascular 
endothelial growth factor-A (VEGF) and angiopoietin (ANGPT)-1 also exert effects on neurons, 
especially in the context of stroke in the central nervous system195. Although VEGF receptors 
(VEGFR) are expressed by neurons196, the role of VEGF signaling in regeneration is not defined. 
Recent clinical studies have reported on VEGF promoting anatomical and functional recovery of 
injured peripheral nerves in the avascular cornea197. 
Extrapolating from these findings, we hypothesize that MPCs positively modulate nerve 
growth activities and that this effect could be augmented through interactions with endothelial. 
These interactions were investigated using the embryonic DRG model in two experimental set-
ups: (1) treatment of DRGs cultured on tissue culture plastic with one or more cell-conditioned 
media and (2) co-culturing of DRGs and MPCs seeded onto a nanofibrous biomaterial nerve 
conduit scaffold. The results showed that neurotrophic differentiation of MPC more strongly 
affected DRG neurite extension on nanofibers, regardless of the presence or absence of 
endothelial cells. Nanofiber-seeding of MPCs increased the gene expression but ultimately 
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resulted in lower conditioned medium (CM) concentrations of several neurotrophic factors. CM 
investigations revealed that VEGF or VEGF-associated molecules in MPC-CM, cultured under 
neurotrophic or growth conditions, were responsible for a large portion of the observed neurite 
length enhancement effect. In comparison, the neurotrophic support activity of MSC-CM was 
largely unaffected by VEGF removal. This observation suggests important differences between 
the neurotrophic secretome of MPCs and MSCs. 
3.2 METHODS 
3.2.1 Construct formation 
Aligned nanofiber constructs (NFCs) were deposited reproducibly on glass slides by 
electrospinning, at ~15 kV difference from a 22G needle placed 15 cm from a rotating mandrel, 
an 11.5% poly-ε-caprolactone (PCL) solution dissolved in 1:1 
tetrahydrofuran:dimethylformamide. NFCs were completed by lining each nanofiber-coated slide 
with silicone glue. NFCs were dessicated overnight to remove any residual solvent, sterilized 
with ethanol and UV-light exposure, and rinsed with PBS before incubation with either 10% 
fetal bovine serum (FBS: Invitrogen) or, serially, with 100 ng/ml polylysine- and 10 μg/ml 
laminin-coating (Sigma-Aldrich: 4°C, overnight). Fiber thickness and orientation were 
determined using scanning electron microscopy and plugins developed for ImageJ/Fiji (BoneJ 
1.4.0198; Directionality 2.0199). 
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3.2.2 Nerve DRG culture 
DRGs, obtained from incubation day 9 chicken embryos via microdissection, were placed on 
sterile, aligned polylysine-and-laminin-coated NFCs. After 24 hours in nerve growth medium 
(Basic Eagle’s Medium, 10% horse serum, 1 nM GlutaMax, Invitrogen) supplemented with 
NGF+ epidermal growth factor (EGF)+ platelet-derived growth factor (PDGF) (Sigma), DRGs 
with or without human co-cultures were cultured for 4 additional days in a combination medium 
of 1:1 conditioned medium:DRG basal medium. Medium was exchanged daily. DRGs were 
fixed and stained immunohistochemically for heavy neurofilament (NEFH) (Sigma; Secondary 
Alexa-Fluor antibodies, Invitrogen). DRGs were visualized with an Olympus inverted 
microscope equipped with a motorized stage controlled through MetaMorph. Resultant mosaic 
images were stitched using Grid/Collection Stitching (Fiji)200; the 10 longest NEFH-positive 
neurite extensions were measured from the geometric center of the original DRG cluster. 
3.2.3 MPC and EC culture 
Traumatized muscle multipotent-progenitor cells (MPCs), isolated as described previously163, (4 
male patients, average age: 24, passage 5-8) were expanded in tissue culture-treated flasks 
(Nunc; Fisher) in growth medium (GM), α−minimum essential medium (MEM) + 10% fetal 
bovine serum (FBS) + antibiotic-antimycotic (PSF) + 1 ng/ml FGF-2 (Invitrogen). Human 
dermal microvascular endothelial cells (ECs) were cultured on tissue culture-treated flasks in 
EGM-2MV medium (Lonza). At 90% confluency, cells were trypsinized (Invitrogen) and 
passaged at 1 x 106/T150 flask. All cells were cultured at 37°C with 5% CO2.  
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3.2.4 Neurotrophic induction 
Cells were seeded at 1 x 103 cells/cm2 on tissue culture plastic (TCP) or NFCs and differentiated 
neurotrophically using a modified 10-day protocol140,141,201. 24 hours after seeding, cells were 
incubated with αMEM + 10% FBS + PSF supplemented with: 10 mM  β-mercaptoethanol 
(BME: Sigma) for 24 hours and 10 mM βME + 35 ng/ml retinoic acid (RA: Sigma) for an 
additional 48 hours; for the six following days, cells were incubated with neurotrophic medium 
(NM; DMEM/Ham’s F12 + PSF (Invitrogen) supplemented with 2% FBS, 2% B-27 
(Invitrogen), 6 mg/ml RA, 1 ng/ml FGF-2 (Sigma), 10 ng/ml PDGF (Sigma), 150 ng/ml 
heregulin (an isoform of neuregulin-1) (Sigma), and 10 µM forskolin (Sigma)).  
Following neurotrophic differentiation, cells were washed and either lysed with TRiZol 
or incubated with basal medium (DMEM + 1% ITSX + 1% PS) for 48 hours to produce 
conditioned medium (CM). CM was centrifuged at 200xg and frozen at -80°C. For DRG co-
culture experiments, tissue culture plastic (P)-cultured NM-MPCs were trypsinized and 
transferred to DRG-containing fibers at a concentration of 1 x 103 cells/cm2. 
3.2.5 EC/MPC culture on nanofibrous constructs  
MPC and EC were seeded on FBS-coated NFCs at various densities in cell-specific growth 
medium; medium was exchanged every two days. Cell viability and density were assessed by 
quantifying Live-Dead fluorescence microscopy images using custom macros written for 
ImageJ/Fiji.  
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3.2.6 Confirmation of neurotrophic induction 
Neurotrophic factor production/secretion into CM was assessed via sandwich ELISAs (R&D). 
RNA was isolated with TRiZol for neural gene expression analysis via RT- followed by q-PCR 
(Superscript III: Invitrogen; 18S rRNA, BDNF, CNTF, GDNF, Nestin, NGF, VEGF: Qiagen).  
3.2.7 Selective VEGF removal 
VEGF was selectively removed from thawed, centrifuged, and filtered CM using neutralizing 
antibodies (mouse IgG, mouse aVEGF; R&D) bound to SpinTrap Protein G beads (Sigma). 
Beads and any bound antibodies/factors were removed from CM by centrifugation at 200xg for 5 
minutes. Bound VEGF was eluted from the beads, and selective binding was confirmed via 
VEGF ELISA (R&D).  
3.2.8 Statistical analysis 
All data were presented as mean ± standard deviation, unless noted. Statistical differences and p-
values were determined by one- or two-way ANOVA and Sidak’s or Tukey’s test, as 
appropriate. 
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3.3 RESULTS 
3.3.1 Exploring MPC- and EC- neurotrophic support 
On TCP, pooled CM derived from P-seeded NM-MPCs (Figure 12) and GM-ECs slightly 
increased DRG neurite extension when mixed 1:1 with basal DRG medium. By contrast, CM 
from NM-MPC:EC-GM mixed with DRG medium (0.5:0.5:1) increased DRG neurite extension 
length to almost 2x that of control DRG.   This finding suggested that a combination of MPC- 
and EC- neurotrophic activities might better support neurite extension on a nerve guide conduit. 
3.3.2 Scaffold fabrication 
Efficient nanofiber-based physical guidance of neurite outgrowth requires the presence of 
appropriately-sized parallel fibers; electrospinning notoriously involves low batch-to-batch 
consistency202. Because multiple batches of NFCs were required for this study, batch-to-batch 
consistency of fiber diameter and orientation were assessed by examining randomly-selected 
scaffolds by scanning electron microscopy. Scaffold nanofibers (average diameter 580 ± 280 
nm) were relatively well-aligned (22± 17o dispersion).  
3.3.3 Cell viability of MPCs and ECs seeded on NFC scaffolds  
High density, long-term culture can result in very high levels of oxidative stress; because nerve 
cultures are very sensitive to oxidative stress203,204, it was necessary to determine the density of 
cells that could be maintained long-term on NFCs. MPCs or ECs were initially seeded at varying 
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densities (0.5, 1, 5, 10 x 103 [k] cells/cm2) on 10 cm2 serum-coated NFCs. Cell density and 
viability were assessed daily for the first three days and after an additional week in culture 
(Figure 13), corresponding to the schedule of neurotrophic induction. Cells were cultured in their 
respective growth media, to allow for maximum proliferation. 
MPC tolerated NFC culture fairly well, reaching an equilibrium density of approximately 
1-5k cells/cm2, but EC coverage and viability dropped steadily over the culture period. Cell 
aggregation contributed to large variations in within- and between- sample viability and density 
measurements. 
Because of these findings, subsequent experiments involving NFC scaffolds were 
determined after short (<5 day) cultures and moderate (1k/cm2) cell seeding densities.  For 
longer term (>5 days) effects on neurite extension and neurotrophic differentiation, ECs and 
MPCs were cultured on TCP. 
3.3.4 Influence of MPCs and EC co-culture on DRG neurite extension  
To assess the potential neurotrophic effect of the combination of MPCs and ECs in the context of 
a nerve guide, DRG were isolated and seeded onto NFC scaffold. To create co-cultures, NM-
MPC, GM-MPCs and/or GM-ECs were added at a final density of 1x103 (1k) cells per cm2 24 
hours after DRG-seeding. EC-MPC co-cultures were seeded 1:1. NEFH-positive DRG-neurite 
extensions were assessed after 4 days of co-culture with daily medium changes (Figure 14). 
The presence of MPCs, regardless of pre-differentiation, increased the observed length of 
DRG neurites. Specifically, NM-MPCs increased the observed neurite length to ~3-to-4-fold 
above the extension lengths of the NFC-seeded DRG alone, confirming the functional utility of 
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the neurotrophic differentiation protocol. The additional presence of ECs caused a slight increase 
in neurite length on the NFC scaffold.  
3.3.5 Scaffold effects on neurotrophic activities 
To assess whether NFC-seeding might have altered NM-MPC-neurotrophic functions, 
NM-MPC were seeded in induction medium onto NFC and TCP at densities of 1k/cm2. 
Neurotrophic gene expression of NFC-seeded NM-MPC did not change significantly compared 
to TCP-seeded NM-MPC except for an increase in VEGF expression (Figure 15 A and B). 
However, pooled CM from NFC-seeded NM-MPC exhibited much lower concentrations of 
cytokines. FGF-2 (130 ± 220 pg/ml) and GDNF (30 ± 50 pg/ml) were detected inconsistently in 
CM derived from TCP-NM-MPC and were not detected in CM derived from NFC-cultured NM-
MPC. CNTF and NGF could not be detected in any samples.  
Similarly, EC culture on scaffolds in EC growth medium resulted in significant changes 
in neurotrophic gene expression (Figure 15 C and D). Only BDNF and VEGF could be detected 
in CM, and NFC-culture severely reduced the amount of neurotrophic growth factors measured 
in EC-CM, perhaps due to protein-scaffold interactions205. This likely explains the diminished 
support observed upon MPC- or EC- co-culture with DRGs versus TCP-derived CM-
neurotrophic support. 
3.3.6 Mechanism of action of neurotrophic MPCs 
VEGF, most commonly known for its role in angiogenesis, is expressed robustly by 
MPCs and, as was shown, secreted in copious amounts upon neurotrophic induction (Figure 15 B 
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and D). The magnitude of secreted VEGF relative to other neurotrophic factors as well as the 
observation of VEGFR206 on the surface of nerves suggested that it might play a stronger in 
MPC-mediated neurotrophic activity than previously realized. To test whether VEGF was acting 
as a mediator of the MPC effect on DRG, anti-VEGF antibodies-bound to Protein G beads were 
used to selectively deplete VEGF from the CM from MPC and EC. VEGF depletion was 
confirmed by ELISA (Figure 16A). VEGF concentrations in control and IgG-treated medium 
were identical (~170 pg/ml), and VEGF concentrations in anti-VEGF samples were below the 
detection limit. VEGF-removal from EC-GM-CM and MPC-CM significantly decreased the 
maximum length of TCP-cultured DRG neurite extensions (Figure 16B), suggesting a 
dependence of the neurotrophic activity of both cell types on VEGF in addition to other MPC-
secreted neurotrophic compounds.  
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 Figure 12: Neurite extension of TCP-seeded DRGs cultured with CM from MPCs and/or 
ECs  
DRG neurite extension increased due to the synergistic effect of NM-MPC-CM and GM-EC-
CM; n = 6. 
 
 
 
 
Figure 13: MPC morphology seeded on NFC scaffold  
Edge-to-edge mosaic images of MPCs stained with Live-Dead assay were obtained at 24 hours 
post-seeding at (A) 0.5k (B), 1k, (C) 5k, and (D) 10k cells/cm2; scale bar = 100 µm. Evidence of 
NFC alignment could be seen in the common orientation of the MPCs. (E) MPC density scaled 
with initial seeding density at early timepoints (days 1 and 3), but eventually converged towards 
1k cells/cm2 by day 9. Because of MPC aggregation on the scaffolds, (F) MPC viability varied 
widely at low timepoints; while still high (>60%), some variability remained by day 9. 
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 Figure 14: Neurite extension of DRG seeded on NFC scaffold upon co-culture with MPCs 
or combination of MPCs/ECs (1:1)  
MPC influence, particularly neurotrophic induction, increased the length of neurite extensions. 
With respect to each treatment group, EC presence did not significantly alter the length of 
observed neurite extensions except in co-culture with NM-MPC. 
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Figure 15: Culture substrate effects on MPC cytokine gene expression  
MPC (A,B) and EC (C,D) cytokine gene expression (A,C), normalized to TCP-controls were 
mildly or positively affected by NFC-culture in almost all cases. Cytokine secretion, however, 
(B,D) was adversely affected by culture on NFC. n = 6. * p< 0.05, ** p < 0.01 from all other 
groups. 
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Figure 16: VEGF production by MPCs and MSCs and effect on neurite extension  
VEGF was present in conditioned medium derived from both MPCs and MSCs (A) and could be 
removed P-CM by indirect immunoprecipitation using VEGF-specific antibodies (versus control 
IgG antibodies). Selective removal of VEGF from control (exogenous VEGF-only) and 1:1 DRG 
medium:cell-conditioned medium groups decreased observed neurite extensions compared to 
IgG-treated mixtures, indicating that VEGF contributes to both MSC and MPC neurotrophic 
function. n=3, **p<0.01. 
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3.4 DISCUSSION 
We have previously reported that that neurotrophic induction of MPC enhances their production 
of neurotrophic factors, most notably BDNF and CNTF.  Extending that work, results from this 
study showed that NM-MPC co-culture and CM from NM-MPC supported neurite extension of 
DRGs seeded on NFC and TCP, respectively, despite adverse effects of the nanofibrous substrate 
on MPC viability and growth factor secretion into the CM.  While consistent, significant 
differences in VEGF or BDNF concentrations in the CM were not observed due to high between-
patient and between-experiment variability, distinctly higher VEGF concentrations were 
associated with neurotrophic induction. 
Our findings showed that the combination of NM-MPCs and GM-EC might best support 
neurite extension (Figure 12), working almost synergistically despite similar concentrations of 
BDNF and VEGF in their respective CM (Figure 15 B, D). Other researchers reported greatly 
enhanced MSC trophic activities upon culture with cellulose-fiber-concentrated CM139; pilot 
experiments testing enhancement of growth factor concentrations revealed that relevant growth 
factor concentrations did not scale with volume depletion. Further, trophic effects of 
concentrated-CM were not markedly better than non-concentrated CM. For this reason, CM, 
without further manipulation, was utilized for all experiments. 
To promote better DRG attachment and growth on NFC substrate, laminin- and lysine-
coatings were utilized, in line with a growing consensus that many aligned fibrous structures 
bearing ECM molecules are beneficial to the ultimate function of a nerve guide conduit207; 
several groups have also investigated physical modifications to the PCL surfaces or 
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chemical/ligand conjugation 76,208 to better support initial nerve attachment and proliferation, and 
work is ongoing with coatings derived from various extracellular matrix (ECM) molecules. 
While fiber culture was ultimately found to be detrimental to MPC-neurotrophic induction but 
not survival (Figure 13), construct-seeded MPCs preferentially supported DRG-neurite 
extension, and the combination of GM-EC and NM-MPC co-culture enhanced this support 
(Figure 14). This suggests that by optimizing the interactions of MPCs and ECs, preferential 
nerve support can be achieved. Proteomic analysis of the secretomes of both cell types might 
elucidate synergistic neurotrophic interactions or potential antagonistic interactions between 
inhibitory factors in either the MPC- or EC-CM, the details of which warrant further study. 
In addition to its well established activity as an angiogenic factor, VEGF has been known 
to affect the neural system33,209. We therefore examined the potential involvement of VEGF in 
the neurotrophic support of MPC-CM and EC-CM.  Following immunoprecipitation of VEGF 
from MPC-CM and EC-CM, neurite extension decreased when compared to the use of control 
antibodies, suggesting that VEGF is required for the promotion of neurite outgrowth (Figure 16).  
IgG control-treated CM, regardless of source, elicited longer neurite extensions. Analysis of the 
control antibody formulation revealed the presence of gelatin versus bovine serum albumin in the 
control antibody formulation versus the anti-VEGF antibody formulation. These protein 
differences could presumably affect the net neurotrophic activity, and further investigations of 
the composition of the CM after VEGF removal will therefore need to be performed. 
Additionally, both neurite VEGF sensitivity (as measured by the density of VEGFR surface 
expression) and available VEGF (as indicated by the absence of soluble and membrane-
expressed VEGFR-1) may be affected by the selective removal of human VEGF. Studies 
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examining those aspects of neurite VEGF responsiveness might shed more light on the exact 
mechanism of MPC-produced VEGF neurotrophic support. 
Within the cell suspension isolated from traumatized muscles, a CD29+/CD34+ vascular 
endothelial progenitor cell (EPC)-like population has been noted143; muscle-derived stem cells 
have additionally been observed to spontaneously express both vascular and neurotrophic 
markers upon culture with neurons210, suggesting plasticity or a mixed culture of these cell 
types207,210. The preferential support by MPCs of nerve cells suggests that the above work could 
be explained by the presence of MPC-derived EPCs. 
Taken together, these findings demonstrate that the neurotrophic activities of MPCs can 
be enhanced by chemical induction, CM-combination with ECs, or co-culture with adult ECs. 
VEGF played a role in the observed positive effect of MPC-CM on DRG neurite extension; 
given its dual role as an angiogenic and neurotrophic factor coupled with the observation of 
enhanced neurite extension under EC influence, future NFC scaffolds could incorporate VEGF 
in an attempt to support both cell types. The detrimental effect of the fibrous scaffold on MPC 
gene expression and measured protein secretion indicates that PCL, in particular, is a sub-
optimal substrate for NM-MPCs. Work with more cell-friendly substrates, including thin ECM-
coatings on the existing PCL scaffold structure, is both ongoing and shows promise in the 
development of a regenerative medicine construct for nerve repair. 
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4.0  INFLUENCE OF INFLAMMATION AND ENDOTHELIAL CELLS ON IN 
VITRO OSTEOGENESIS OF TRAUMATIZED MUSCLE PROGENITOR CELLS 
4.1 INTRODUCTION 
Within the first 48 hours after traumatic injury, increases in circulating levels of pro-
inflammatory molecules, including interleukin (IL)-6, IL-1β, tissue necrosis factor (TNF)-α, 
macrophage-interaction promoting IL-18, C-reactive protein (CRP), sepsis-correlated 
procalcitonin, and anti-inflammatory IL-10, are observed211. Previous studies have shown that 
excess amounts of IL-6 have a detrimental effect on the hallmark-ability of adult tissue-resident 
stem cells to differentiate along mesenchymal (adipose, cartilage, bone) lineages; IL-6 promotes 
“stemness” and cell replication over differentiation172 and is produced endogenously by 
microvascular endothelial cells (ECs)212. IL-1β and TNF-α show similarly detrimental effects on 
mesenchymal differentiation with slightly decreased proliferation of mouse bone marrow-
derived mesenchymal stem cells (MSCs)213.  
We have previously identified multipotent progenitor cells (MPCs) in blast-traumatized 
human skeletal muscle.163  These cells are characterized by their ability to differentiate along 
hallmark mesenchymal lines and their similar surface epitope profile compared to human bone 
marrow MSCs163.  Although more easily-isolated and more abundant per unit tissue134 than bone 
marrow- or adipose-derived MSC subtypes, suitable MPC-donor tissue may be limited due to the 
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severity of some limb-blast injuries; this potential limitation requires extensive in vitro expansion 
of any isolated MPC to obtain sufficient cell number for use in a regenerative medicine therapy. 
Culture-related changes in MSC stem cell gene expression and DNA methylation but not stem 
cell surface markers have been reported214,215. Previous work indicated no stem cell marker 
population differences between MPC and MSC at low passage number139 as revealed by flow 
cytometry; however, slight differences in fluorescence intensity of each marker were 
observed139. It has been noted that MSCs do not lose stem cell marker expression upon long-term 
cultures, even if their differentiation capacity has been compromised214.   
Interestingly, the inflammatory factors IL-1β and TNF-α are upregulated in MPCs versus 
non-traumatized muscle cell controls213. In bone marrow-derived MSCs, a possibly related and 
more extensively characterized stem cell population that also exhibits bone-forming activity, low 
levels of TNF-α (<10 ng/ml) appear to enhance early osteogenesis, indicated by alkaline 
phosphatase (ALP) expression and early osteogenic gene expression, while high doses (20-50 
ng/ml) of TNF-α suppress osteogenesis and encourage a neural phenotype through nuclear factor 
kappa-light-chain-enhancer of activated B cells (NFκB) signaling. In comparison, IL-1β appears 
to suppress osteogenic gene expression but promote mineralization (usually a marker of mature 
osteogenesis) at low doses, with unknown activity at high doses216. One of the well-recognized 
tissue responses to traumatic injury is heterotopic ossification (HO), observed most commonly in 
skeletal muscle sites adjacent to the traumatized site.217 While the exact etiology of HO is 
incompletely understood and is currently being investigated218, it is likely that the presence of 
inflammatory factors enhances the osteogenic differentiation of the resident MPCs in skeletal 
muscles. 
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Another possible influence on MPC osteogenesis may be from the vasculature, i.e., 
endothelial cells. Endothelial cellshave been observed to affect the osteogenic differentiation of 
MSCs; co-cultures of MSCs with endothelial cells showed accelerated bone phenotypes216,219. 
Endothelial cell activity, however, is known to be affected by inflammation; specifically, IL-1β 
and TNF-α disrupt stable endothelial networks (in vitro markers of angiogenesis) noticeably (5 
ng/ml TNF-α) or slightly (5 ng/ml IL-1β), and alter the proliferation of endothelial cells173. The 
effect of these disrupted angiogenic systems on MPC osteogenesis is unknown.  
In turn, MSCs and MPCs are known to regulate angiogenesis. MPCs cause proliferation 
of ECs141, and various types of MSCs have noted anti-inflammatory properties and can stabilize 
endothelial cell networks220,221.  Additional, new observations on the effect of MPCs on the 
organization of endothelial networks and other aspects of angiogenesis are reported in the second 
chapter. 
The studies described above clearly suggest that endothelial cells and MSCs interact 
dynamically and regulate one another in the wound environment. It is thus reasonable to 
postulate that this paracrine regulation, in turn, affects many aspects of tissue healing and 
regeneration including, but not limited to, osteogenesis and angiogenesis; these interactions have 
not been characterized with respect to MPCs. As MPCs stabilize the angiogenic functions of 
endothelial cells, it is hypothesized that endothelial cells reciprocally stabilize the osteogenic 
differentiation capacities of MPCs, dampening the deleterious effects of an inflammatory 
environment and promoting a mature, osteogenic MPC-phenotype. This hypothesis is tested here 
by examining the effect of adult human dermal EC-modulated inflammation on the osteogenic 
differentiation of MPCs and MSCs. While inflammation promoted a unique, mineralizing, but 
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immature phenotype, the presence of ECs or EC-conditioned medium (EC-CM) aided the 
maturation of MPC cultures or co-cultures. 
4.2 METHODS 
4.2.1 Primary MPC isolation 
MPC2-4 (Appendix A) were obtained following debridement of blast-traumatized wounded U.S. 
military personnel with Institutional Review Board (IRB) approval (Walter Reed National 
Military Medical Center). Fascia-free minced muscle tissue (200 µg) was enzymatically digested 
for 2 hours (Dulbecco’s Modified Eagle’s Medium, DMEM; GIBCO; 0.5 mg/ml collagenase 2, 
Sigma) at 37°C under gentle agitation, as originally described by Jackson, et al163. MPC were 
strained through a 40 µm cell strainer and pelleted by centrifugation at 200 x g for 5 minutes. 
Cells were resuspended in DMEM, 10% stem cell culture-approved fetal bovine serum (FBS; 
GIBCO), and 5% penicillin-streptomycin (PSF; GIBCO), plated in a T150 tissue culture flask 
(Corning), and allowed to adhere overnight at 37°C and 5% CO2. Cells were then washed 
extensively with phosphate-buffered saline (PBS; GIBCO) and cultured in DMEM, 10%FBS, 
and 3% PSF, with daily PBS washes, at 37°C under 5% CO2 until confluent. 
4.2.2 Primary MSC isolation and storage 
MSC3-5 (Appendix A) were obtained after flushing scissor-minced trabecular bone removed 
from the femoral heads of patients undergoing total hip arthroplasty (IRB approval, University of 
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Washington) rinsing medium (α-Minimal Essential Medium: α-MEM, 1% PSF; GIBCO). The 
cell-enriched rinsing medium was strained through a 40 µm cell strainer, and the resulting cells 
pelleted at 300 xg for 5 minutes. Cells were washed with rinsing medium and pelleted twice 
before resuspension in growth medium (rinsing medium + 10% FBS + 1 ng/ml basic fibroblast 
growth factor: FGF-2; Fisher). Cells were allowed to adhere to T150 tissue culture flasks and 
cultured in growth medium at 37°C under 5% CO2 until confluent.  
 Upon reaching confluency, cells were washed in PBS, trypsinized (Invitrogen), counted 
by a calibrated, automated cell counter via Trypan Blue exclusion (CedEx; Roche), and frozen (-
200°C) at 1x106 live cells/vial in 1 ml Freezing medium (Invitrogen) at passage 0 (p.0). Passage 
numbers were incremented upon thawing. 
4.2.3 Cell culture expansion 
All expansions were performed on tissue culture-treated plastic T150 or triple flasks (Nunc/BD) 
at 37°C in 5% CO2.  MPCs and MSCs were maintained in growth medium, exchanged every 3-4 
days, for expansion. ECs were expanded using EGM-2MV Bullet Kit (Lonza). Upon reaching 
70-90% confluency, cells were trypsinized, counted, and seeded into new flasks, utilized for 
experiments, or frozen at 1E6/vial (Freezing medium: Invitrogen).  
 
4.2.4 CM generation 
ECs were pre-seeded at an initial density of 1x104 cells/sq. cm in EGM2-MV for 24 hours. Just 
prior to incubation with IL-1β-supplemented or non-supplemented basal medium 
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(DMEM+1%PSF+1% Insulin-Selenium-Transferrin-X; Invitrogen), cells were washed with PBS 
and Hanks-buffered salt solution containing calcium and magnesium (HBSS++; GIBCO). EC-
conditioned medium (EC-CM) with supplements of 5- or 10 ng/ml IL-1β were generated by 
incubating ECs with serum-free basal medium for 48 hours. Non-cell conditioned control CM 
was generated by incubating basal medium with or without IL-1β in empty flasks at 37°C under 
5% CO2. All CM samples were centrifuged at 200xg for 5 minutes before the supernatant was 
frozen at ≤-20°C for later use. At the time of use, CM samples were thawed, centrifuged at 200 
xg for 5 minutes, and filtered through 0.2 μm filters (Steri-flip; Millipore) before use. 
4.2.5 Inflammation/angiogenesis-moderated in vitro osteogenesis 
Conditioned medium (CM) generated with ± 5 ng/ml IL-1β (± I) was used to supplement 
the medium of MPC/MSC or EC-co-cultures undergoing in vitro osteogenesis using a standard 
cocktail (Final composition: DMEM+10% FBS+2% PSF+50 μg/ml ascorbic acid, 1 nM 
dexamethasone, 10 mM betaglycerophoshate; all supplements from Sigma-Aldrich) as described 
below (Figure 17). Cells were seeded at 2x104 cells/cm2 in tissue culture-treated 24- or 48-well 
plates (Costar). Medium was changed every 2-3 days. 
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Figure 17: Effect of conditioned medium on MPC and MSC osteogenic differentiation 
Unless noted, all cells were cultured for up to 21 days under osteogenic conditions by adding 
osteogenic supplements to CM generated under cell-free conditions (blue control medium). 
MPCs or MSCs, represented as dark blue cells, were seeded at 2x104 cells/cm2; ECs were seeded 
in control cultures at the same density and are represented as red cells. For co-cultures, MPCs or 
MSCs were loaded at 5/6 of the original seeding density, and the remaining 1/6 of the culture 
filled by ECs after the firm attachment of MPC/MSC (denoted by +EC). The effect of EC-CM 
and EC-CM+I was also tested on MPC-only and MSC-only cultures (green bar). 
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4.2.6 Osteogenesis assessment 
Cell lysate obtained using 0.25 ml 0.4% SDS in diH2O per well of a 48-well plate was used to 
quantify alkaline phosphatase activity (p-nitrophenyl phosphate substrate; NPP, Sigma), which 
was normalized to DNA, extracted using the Allprep protocol (Qiagen) and measured using the 
Pico Green assay (Invitrogen). Reported cellularity was normalized to culture surface area and 
equivalent ALP cell lysate concentrations; co-culture specific activity was further normalized to 
the initial amount of osteogenic cells (MPC or MSC). 
Osteogenesis in cultures was assessed after paraformaldehyde fixation at early time 
points (day 7) with alkaline phosphatase staining (Sigma kit). Paraformaldehyde-fixed samples 
were stained with Alizarin Red S (EMS) to visualize late osteogenesis calcium deposition at day 
21. All stained samples were visualized on an Olympus CKX41 inverted microscope at 200x. 
Relative amounts of matrix-bound Alizarin Red S were quantified by incubating thoroughly 
washed samples with 10% acetic acid for 30 minutes and measuring absorbance (550 nm) of 
centrifuged (200 xg), isopropanol-diluted supernatant.  
4.2.7 Gene expression analysis 
RNA was extracted from samples using RLT buffer supplemented with 10 nM β-mercapto-
ethanol (Qiagen; Bio-Rad). RLT-lysed cells were stored at -80C. Upon thawing, samples were 
processed with RNEasy (or Enzymax brand) spin columns, according to the manufacturer’s 
instructions. RNA purity and concentration were determined by 260/280 and 260/230 readings 
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(NanoDrop 2000C). RNA was converted to cDNA using SuperscriptIII with random hexamers 
(Invitrogen; BioRad iCycler) and stored in small, pooled aliquots at -80C. cDNA corresponding 
to 10 ng original RNA was loaded in triplicate wells of a 96 well qPCR reaction plate with 1x 
SYBR Green Master Mix (Invitrogen) and 100 nM each forward- and reverse- primers (Table 2); 
following 40 thermal cycles between 95-60C (ABI 7900 HT; ABI StepOne Plus), software-
computed osteogenic or EC-specific expression threshold values were compared to a pooled 
cDNA standard curve (used to normalize expression between plates) to determine gene 
expression compared to 18S control genes. Ct values higher than 35 were rejected. 
 
Table 2: Primer sequences for qPCR analysis 
 
Gene Primer sequence (5’ – 3’)* 
Forward Reverse 
18S ribosomal RNA 
(18S) 
-GTAAC CCGTT GAACC CCATT- -CCATC CAATC GGTAG TAGCG- 
Alkaline phosphatase 
(ALP) 
-TGGAG CTTCA GAAGC TCAAC 
ACCA- 
-ATCTC GTTGT CTGAG TACCA 
GTCC- 
Bone morphogenetic protein 2 
(BMP) 
-ACCCG CTGTC TTCTA GCGT- -TTTCA GGCCG AACAT GCTGA G- 
Bone sialoprotein II 
(BSP-II) 
-GCAGT AGTGA CTCAT CCGAA 
GAA- 
-GCCTC AGAGT CTTCA TCTTC 
ATTC- 
Collagen, Type I, α1 
(COL) 
-TCCTG CTCCT CTTAG CG- -CATGGT ACCTG AGGCC GTTC- 
Osteocalcin 
(OCN) 
-TCACA CTCCT CGCCC TATTG- -GAAGA GGAAA GAAGG GTGCC- 
Runt-related transcription factor 2 
(RUNX2) 
-CAACC ACAGA ACCAC AAGTG 
CG- 
-TGTTT GATGC CATAG TCCCT CC- 
Cluster of differentiation 31 
(CD31) 
Proprietary sequences** 
* Purchased from IDT. **RT2 Profiler primers purchased from Qiagen. 
 
 
 80 
4.2.8 Stem cell marker surface expression over time in culture 
At low (3) and high (10) passage, MPC and MSC (n=3) were trypsinized, inactivated 
with FBS, and resuspended with FACS buffer (Ca2+- and Mg2+-HBSS buffered salt solution + 5 
ml FBS + 0.01% sodium azide: Invitrogen). After blocking with 10% mouse serum in HBSS, 
2.5x105 FACS buffer-washed MPC were incubated with appropriate antibodies (Table 3) and 
fixed in 4% paraformaldehyde. Marker expression was analyzed on a BD FACSAriaII, with cell- 
and passage-dependent gating determined by an experienced, independent analyst based on IgG-
matched patient controls. 
 
Table 3: Flow cytometry markers and staining conditions*  
  
 
PE-conjugated 
antibody target 
BD Biosciences catalog 
number 
Antibody distribution 
(μl/1M cells) 
Literature-reported 
MSC threshold115 
CD19 555413 20 <5% 
CD34 550619 5 <5% 
CD45 557059 20 <5% 
CD73 550257 20 >95% 
CD90 555596 0.2 >95% 
CD105 560839 20 >95% 
HLA-DR 560943 20 <5% 
IgG-1a isotype control 554680 assay-dependent - 
CD14 555574 20 <5% 
IgG2-a isotype control 558595 assay-dependent - 
 
* Negative markers exclude MSCs from hematopoietic, monocyte/macrophage, B-cell, or leukocyte origin, and in 
the case of HLA-DR, exclude inflammation-activated (‘stimulated’) MSCs121. Positive markers are not unique to 
MSCs, but associate MSCs with the vasculature, fibroblasts or activated endothelium, and mineralizing ability220–222. 
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4.2.9 Statistical analysis 
Data were analyzed in Excel and GraphPad Prism. Data were presented as mean ± standard 
deviation. Outliers were removed with Grubbs’ test. Student’s t-tests were used for comparison 
when 3 or fewer conditions were compared. For larger data sets, GraphPad Prism was used to 
perform one- or two-way ANOVA with multiple comparisons, using Sidak’s or Tukey’s 
corrections for multiple comparisons, respectively.  
4.3 RESULTS 
4.3.1 Generation of inflamed endothelial cells 
To test whether IL-1β-treated ECs were affected by the presence of the cytokine, ECs plated on 
Matrigel were treated with 5 and 10 ng/ml IL-1β. As shown in Figure 18, IL-1β treatment was 
seen to result in shortened and disrupted EC networks. Because the lower concentration was 
functionally effective, 5 ng/ml was chosen for subsequent experiments involving inflamed ECs. 
The IL-1β effect was also confirmed by comparing angiogenic gene expression via PCRArray of 
EC grown in basal medium (CM) to EC grown in basal medium with IL-1β supplementation 
(CM+I) for 2 days. Despite equal initial seeding density, EC+I cultures contained fewer cells 
than control cultures by the end of the incubation period used for CM collection, consistent with 
literature observations173. Specifically, three genes were significantly (>2-fold, p<0.05) 
upregulated in IL-1β cultures over control cultures: chemokine C-X-C ligand (CXCL)-6, 
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interferon (IFN)-β1, and insulin-like growth factor (IGF)-1. IL-1β was not detected in EC-CM, 
and the concentration of IL-1β had dropped to 59 ± 12 pg/ml in EC-CM+I, which was still well 
within the IL-1β concentration range reported to affect MSC in vitro osteogenesis97. 
 
 
 
Figure 18: Effect of IL-1β on EC cord formation on Matrigel   
Treatment with 5 ng/ml IL-1β was sufficient to decrease EC Matrigel cord-formation estimated 
based on cord branching and length of cord network. 
 
 
 
 83 
4.3.2 Inflammation associated osteogenesis: Osteogenic gene expression 
To assess the effect of IL-1β treatment on osteogenesis, osteogenic gene expression was assessed 
after 4 and 14 days in osteogenic cultures of MPCs and MSCs supplemented with cell-free CM 
or CM+I (Figure 19). When normalized to day 4 growth osteogenic marker expression, all 
osteogenic markers increased with time in culture. Early osteogenesis markers, ALP and 
RUNX2, were expressed more strongly by MSCs than MPCs. Expression in both cell types was 
decreased due to inflammation, consistent with previous reports225. MPCs did not express BSP-II 
at detectable levels. Interestingly, MPCs exhibited higher levels of OCN, COL-I, and BMP2 
gene expression than MSCs. This indicates that MPCs might encourage bone formation rather 
than creating bone themselves.  
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Figure 19:  Inflammation decreased osteogenic gene expression in MPC and MSC cultures  
Osteogenesis of MPCs and MSCs was assessed on the basis of RT-PCR analysis of gene expression after 4 and 14 days in culture. For 
cultures with and without IL-1β, pooled MPC- and MSC- ALP, RUNX2, collagen-IA1 COL-I, BMP2, BSP-II, and OCN gene 
expression were examined at d.4 and d.14; marker expression was normalized to 18S and d.4 growth gene expression; n=3, **p<0.01, 
log scale. Osteogenic gene expression increased with culture time, and the presence of IL-1β contributed to lower osteogenic gene 
expression when compared to non-inflamed controls at the same timepoint. Mature osteogenic gene expression was less reliable in 
MPCs when compared to MSC, frequently falling below the assay detection limit (Ct > 35). CD31 gene expression was initially high 
in EC cultures and low in MPC/MSC cultures but dropped below the assay detection limit by day 14. 
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4.3.3  EC co-culture and survival 
To more directly address the bone-forming abilities of MPCs in a physiological context, 
osteogenic cells were next seeded in co-culture with ECs. To address the relative contribution of 
seeded cells to observed culture activity, it was necessary to determine the relative amount of 
each cell in co-culture. The survival of CD31+ ECs was estimated by ELISA of cell lysates 
prepared in the presence of protease inhibitors (Figure 20).  
 
 
 
Figure 20: Persistence of ECs in monoculture and co-culture with MPCs/MSCs upon 
treatment with IL-1β   
CD31 was detected in EC monoculture and co-culture cell lysate and normalized to the initial EC 
population. Decreased specific CD31 production (production/cell) was observed in all co-culture 
groups with increasing culture time, and specific CD31 content increased slightly due to IL-1β 
presence except in MSC co-cultures. 
 
 
CD31 cell content increased in EC cultures but decreased in co-cultures over time. The 
decline was increased by IL-1β exposure. This indicates a loss of EC or EC-CD31 production 
over time, either through MPC/MSC preferential proliferation, EC CD31-downregulation, or 
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MPC-EC/MSC-EC cell fusion226. Evidence from CD31 immunofluorescence suggests the latter 
two possibilities, as global CD31+ staining was observed in co-cultures after 24 hours. While EC 
cell death could also explain the CD31 loss, the magnitude of CD31 loss does not correlate with 
the culture cellularity (Figure 21). Per-cell DNA content did not vary significantly by cell type at 
the start of osteogenic culture; however, MSCs proliferated rapidly, reaching ~4x the cellularity 
of MPCs by day 4 and maintaining that difference throughout the culture period. 
4.3.4 Functional effects of inflammation and co-culture: ALP activity 
Because ALP activity, along with exogenous phosphate, is required for in vitro osteogenesis94, it 
was assessed at an intermediate time point (day 7) in EC-influenced co-cultures. Consistent with 
observations reported elsewhere98, decreases in ALP production due to IL-1β could be observed 
by Naphthol AS-BI ALP-staining and quantified by osteogenic cell-normalized NPP conversion 
(Figure 22 A and B). Surprisingly, EC co-culture further diminished observed ALP activity, but 
these decreases could be partially rescued by the addition of EC-CM. ALP activity could be 
attributed almost solely to MPCs or MSCs because EC-specific ALP activity was negligible. 
This suggests that MPCs are uniquely responsive to soluble factors released by endothelial cells, 
and that such factors could promote bone formation by MPCs. 
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4.3.5 Functional effects of inflammation and co-culture: Mineralization and selected gene 
expression 
To assess the mineralization of osteogenic co-cultures, cultures were stained at day 21 with 
calcium-binding Alizarin Red S.  After imaging, mineralization was quantified by solubilizing 
the Alizarin Red S (Figure 23). MPC+EC+I exhibited the strongest mineralizing phenotype 
among MPC cultures. Gene expression of ALP, RUNX2, OCN, and BMP2 in MPC+EC+I was 
highest among all 14-day cultures groups (Figure 24), indicating that MPCs in an inflamed and 
angiogenic environment may contribute preferentially to de novo bone formation. EC-CM 
affected osteogenic cultures similarly but to a lesser extent than EC co-cultures (Figure 25). 
 
 
 
Figure 21: Osteogenic culture cellularity of (A) MPCs and (B) MSCs during osteogenic 
differentiation in vitro   
Cellularity based on DNA analysis did not vary significantly between culture groups at each 
measured time point. All cell types exhibited similar DNA content per cell on day 0. MSC 
proliferated faster than MPC, as cellularity measurements at nearly all timepoints were roughly 
four times larger in MSC- versus MPC-cultures (including growth controls). The observed 
decrease in isolated DNA at day 21 could be a result of either cell death or double-stranded 
DNA-depletion in solution, based on binding to insoluble products or DNA destruction due to 
increased shear. Day 21 samples required much more force to break apart the dense mineral and 
cell aggregates that had formed. 
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Figure 22: Inflammation decreased ALP activity in MPC/MSC cultures regardless of EC 
co-culture or EC-CM   
(Top) Early time-point osteogenic cell-normalized Naphthol AS-BI staining (Top) and ALP 
activity (Bottom; as indicated by NPP conversion). n=3; *,p<0.05; **, p<0.01. Because EC-ALP 
activity was extremely low, co-culture specific ALP was normalized to the initial amount of 
osteogenic cells. The presence of IL-1β inhibited ALP activity, and the effect could not be 
overcome by EC influence (either co-culture or EC-CM). EC-CM partially rescued MPC ALP 
activity, but not MSC, suggesting that MPC are more easily routed towards an osteogenic fate by 
EC-produced soluble factors. 
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 Figure 23: Inflammation overwhelmed the influence of EC co-culture and EC-CM on 
MPC/MSC osteogenesis in vitro as indicated by matrix mineralization   
(Top) Alizarin Red S (ARS) staining, and (Bottom) quantification of (A) MPC and (B) MSC 
mineralization revealed a strong IL-1β-dependence with a much stronger mineralization response 
by MSCs versus MPCs; n=3, **, p<0.01. EC co-culture and EC-CM appeared to have less of an 
effect on mature osteogenesis when compared to IL-1β, and the combination of MPCs and ECs 
resulted in a strongly mineralizing phenotype. Note that comparable mineralization was achieved 
by ~1/4 the number of MPCs versus MSCs in the MPC+EC+I culture. 
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 Figure 24: Osteogenic gene expression increased due to inflammation in MPC- and MSC- EC co-cultures  
Some of the strongest osteogenic gene responses were observed in MPC-EC co-cultures at d.14. Except for MSC late osteogenesis 
markers, IL-1β increased osteogenic expression in co-cultures by d.14, indicating that inflamed-ECs interact with MPCs to promote 
osteogenesis, but EC effect on MSC is less strong. 
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 Figure 25:  Osteogenic gene expression increased due to inflammation in EC-CM-treated MPC and MSC cultures  
Gene expression patterns were similar to those observed without EC-CM with respect to IL-1β effects; EC-CM appeared to slightly 
decrease early osteogenic genes (ALP and RUNX2) and induce stronger BMP2, BSP-II, and OCN gene expression by day 14 when 
compared to non-EC-CM cultures. This indicates that EC-CM may drive MPCs and MSCs towards a more mature, mineralizing 
phenotype. 
 92 
4.3.6 Stem cell marker expression over time 
Because differentiation ability can be lost with in vitro age214, MPC and MSC stem cell 
marker expression was assessed at early and late cell passage (p.3 to p.10). One patient from 
each studied group was excluded due to extreme loss of stem cells markers by p.10 (Figure 26). 
Although statistical comparisons were not possible, trends indicating enrichment of CD34+ 
MPCs and maintenance of or increases in stem cell marker expression were observed. This 
indicates that tissue-resident or tissue-recruited progenitor cells may not strictly be termed MSCs 
despite their differentiation and trophic abilities; if possible, cells from more patients should be 
investigated to draw conclusions about MPC versus MSC differences in stem cell marker 
expression. 
Analysis of work from other chapters revealed that the excluded populations, MPC1 and 
MSC3, were often excluded via outlier testing from contributing to global descriptions of MPC 
or MSC activities. This affirms the need for careful functional testing, including the effect of 
extended proliferation, of autologous cells before they are utilized therapeutically. 
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Figure 26: Stem cell marker profile changes as a function of MPC and MSC culture time  
Single replicate changes in flow cytometry measurements of stem cell markers were assessed in 
MPC (A, C) and MSC (B, D). Neither studied population strictly fit the minimum definition of a 
stem cell despite functional MSC-screening. Except for CD34 which increased with cell passage 
in both populations, MPCs stem cell marker expression appeared to drift towards full stem cell 
marker expression (loss of CD14, CD19, CD45, and HLA-DR with gains in CD90 and CD105 
expression) with increasing passage; MSC stem cell marker expression also drifted towards 
increased stem cell marker expression, except for gains in HLA-DR expression coupled with a 
loss of CD105. 
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4.4 DISCUSSION 
The use of autologous multipotent cells for limb repair is an intuitive and desirable therapeutic 
goal. There is mounting evidence that the highly-inflamed and angiogenic environment of a 
blast-traumatized wound bed serves as a potent source of culture-expandable, uniquely active 
traumatized multipotent progenitor cells, the MPCs. Our recent and past work has explored the 
effect of in vitro conditioning of these cells for eventual therapeutic purposes, with some results 
hinting at their possible involvement in blast-associated diseases136; in other words, there is 
concern over the biological activity states of these cells, once they are returned to a wounded 
tissue microenvironment. The current work describes in vitro studies aimed at elucidating 
changes to MPC osteogenic activities induced by their environment, chiefly in the context of 
both inflammation and angiogenic influences. In addition, MPC activities were compared to 
better-characterized mesenchymal stem cells (MSCs), such as bone marrow-derived MSCs in an 
attempt to identify cell-source-related activity differences. 
Consistent with previous comparisons, MPCs were found to be less osteogenic than 
MSCs in a non-inflamed setting than MSCs139. The above work found lower MPC osteogenic 
gene expression, ALP activity, and mineralization than MSCs, except for OCN and COL-I gene 
expression, under normal osteogenic culture. In the presence of IL-1β, MPCs and MSCs 
preferentially mineralized; this mineralization was not associated with an increase in osteogenic 
markers (Figure 19). In fact, IL-1β culture generally decreased later osteogenic gene expression 
and early ALP activity (Figure 22). These findings are consistent with work involving human 
MSCs reported elsewhere; IL-1β presence between 0.1-10 ng/ml increased culture mineralization 
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at day 14, later proven to be dependent on ALP activity at that later time point, while inhibiting 
COL-I and RUNX2 gene expression225.  
The small number of patients available for comparison limits the strength of this study. 
With two exceptions, in vitro age did not affect the stem cell marker expression of tested MPC 
and MSC populations although neither population exactly matched literature-reported MSC 
descriptions. Surprisingly, MPCs, though derived from an inflamed environment, exhibited 
lower HLA-DR expression than MSCs, excluding MPCs from the category of ‘activated' MSCs. 
MPC gained hematopoietic/endothelial104 CD34 expression with culture time, consistent with 
reports of an initial CD34+ subpopulation within unsorted muscle-derived cell suspensions143 and 
initial differences in CD105 expression, denoting vascular origins222, between MPC and MSC 
disappeared by late passage. The presence of CD34+ cells within the MPC population is 
particularly troubling given the association of CD34+ cells with heterotopic ossification in human 
genetic disorders. Combined with the work of previous chapters, this work indicates that MPCs 
must be screened rigorously for their stem cell activities and trophic potential before 
consideration for use in a patient. 
Focusing on non-inflamed comparisons, EC influence on MPC osteogenesis was broadly 
similar to that reported in the literature for various fibroblast-endothelial systems. Co-culturing 
of osteoblasts and HUVEC (human umbilical vasculoendothelial cells) resulted in increased 
osteoblast ALP gene expression; co-culture also suppressed OCN expression, likely mediated by 
p38 MAPK227, but this increase could be associated with higher BMP2 gene expression levels in 
ECs versus MSCs/MPCs228. One key difference between the findings reported here from 
previous findings was a decrease in ALP activity with co-culture when compared to MPC/MSC-
culture alone, perhaps due to the use of ECs versus HUVECs or activity normalization (DNA 
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versus protein)96. A global loss of CD31 production and poor gene expression was observed 
under osteogenic conditions (Figure 20), likely due to long-term culture incompatibilities 
between MPCs/MSCs and ECs229. BMP2 gene expression increased under the influence of both 
EC and, most strikingly, EC-CM. Increased collagenous matrix deposition under the influence 
EC-CM suggests a hyper-mineralizing influence of EC-CM230. 
In experiments confirming the effect of inflammation on ECs, moderate changes in EC 
network forming abilities (Figure 18) were consistent with changes observed with more 
commonly-used HUVECs231. Three inflammation-upregulated angiogenic molecules played 
significant roles in host immune response and osteogenesis232,233. CXCL6 is known to recruit 
neutrophils, affect EC proliferation, and is produced by fibroblasts upon IL-1β stimulation, but 
no effects have been reported on osteoblast or MSC differentiation174,233. IGF1 regulates the 
delicate balance between adipogenesis and osteogenesis in MSC and, through its binding with 
the IGF-receptro (IGFR), increases osteoblast proliferation234. IL-1β-induced IL-6 is known to 
suppress osteoblast activity90, pressuring differentiated progenitor cells to revert to their stem 
origins172. Taken together, these increases suggested that inflamed ECs might differentially 
regulate osteogenesis when compared to their non-inflamed counterparts, promoting proliferation 
and suppressing osteogenic differentiation, depending on the responsiveness of MPCs or MSCs.  
EC-influence in the presence of inflammation could not be so easily matched to 
observations reported elsewhere. EC-CM+I-induced gene expression changes were internally 
consistent with the hyper-mineralizing phenotype observed using Alizarin Red S staining (Figure 
23). Those observations of enhanced MPC-osteogenesis in the presence of EC-CM+I were 
particularly surprising, given reports of suppression of osteogenesis by inflamed EC through the 
actions of IL-6; however, one possible explanation for the contrary finding could be the IL-6 
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stimulated release by MSCs of soluble IL-6 receptor235,236. This MPC-upregulation of an anti-
inflammatory molecule would make sense if MPCs were primed to dampen inflammation, as has 
been suggested by in vitro work with T-cells142. MSCs, perhaps because they were not 
previously activated, exhibited expected, distinctly lower mature osteogenesis marker expression 
due to inflamed-EC influence (Figure 24 and Figure 25). 
This study faced several limitations. Because such decreases have been observed in 
MSCs in many previous experiments, this work assumes that gene expression decreases 
correlated with changes in the cellular microenvironment. Future work would need to confirm 
functional changes in COL-I deposition and serum OCN and BMP2 concentrations to draw full 
conclusions about the effect of IL-1β and cell source on osteogenic potential. Additionally, 
because MSCs from older females were utilized in this study, age- and sex-related differences 
could explain the observed magnitude differences in OCN gene expression between MPCs and 
MSCs81. The opposite responses to IL-1β of MPCs versus MSCs might be attributed to source-
related differences except for the following two observations.  
Trauma appears to mobilize an adherent, proliferative, osteogenic cell type ultimately 
derived from the bone marrow237, and non-traumatized muscle-derived MPCs were shown to 
exhibit a strongly mineralizing phenotype, among other phenotypes relevant to heterotopic 
ossification238.  In addition, interaction with monocytes and macrophages, among other cell 
types, was found to alter osteogenesis in vivo239,240. While the question of ultimate origin of 
MPCs and their in vivo efficacy therefore remain unanswered, this work provides clear evidence 
for tissue trauma-related differences in the angiogenic- and inflammation-responsive osteogenic 
potential of the muscle-derived multipotent cells. To gain further insight into the effect of trauma 
on various multipotent cell activities without cell-sourcing questions, work is ongoing to 
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compare non-traumatized and blast-traumatized muscle-progenitor cells derived from cadaveric 
mice.  Such a model has the added benefit of recapitulating the precise events thought to initiate 
the higher incidence of HO observed in blast-traumatized patients15.  
4.5 CONCLUSIONS 
Heterotopic ossification affects a significantly larger percentage of blast-traumatized versus non-
blast traumatized patients. Work is ongoing to discover a mechanistic reason for this difference, 
and intense interest has been focused on MPCs in recent years towards that end6. Recent work 
has identified a promising MPC subpopulation that may contribute preferentially to the 
formation of HO nodules143. Despite the substantial characterization work accomplished in the 
past several years, very scarce data is available about the modulatory capacity of MPCs with 
respect to other cells, namely T-cells and ECs139,142, but more importantly, no information has 
yet been reported on the modulating effect of the wound environment on MPCs. The work 
presented above is the first to examine cell-cell interactions on MPC osteogenesis. 
Taken together, the presented data indicate that when angiogenic and inflammatory 
stimuli are present, MPCs are more responsive to osteogenic stimuli than MSCs. This work 
provides evidence that MPCs exhibit a more mature osteogenic phenotype as a direct result of 
the combination of inflammation and the activities of ECs. Inflammation, in the form of 
exogenous IL-1β, significantly increases MPC-mineralization but inhibits osteogenic gene 
expression, while EC influences, both contact-mediated and through soluble factors, seem to 
promote a more mature, matrix-depositing, osteoblast-phenotype. This is encouraging in the 
limited context of bone regenerative therapies, but, ultimately worrying from a patient 
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perspective, as cell migration from an implanted regenerative medicine construct could nucleate 
heterotopic ossification due to inflammation inherent with normal wound healing. Caution 
should therefore be applied in developing potential therapies that seek to restore limb skeletal 
structure or function using MPCs. 
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5.0  SUMMARY AND FUTURE DIRECTIONS 
Under current treatment methods for blast-damaged limbs, the average 24-year-old battlefield-
injured military combatant awakens from life-saving surgery to an existence that, at best, 
requires either expensive prosthetic use or the sub-optimal function and probable pain of a 
scarred limb. Efforts to improve the function of restored limbs and to understand some of the 
orthopedic causes of complications are ongoing. Considerable interest has been generated by the 
idea of using autologous multipotent progenitor/stem cells, particularly MPCs, therapeutically, 
but as with MSCs, ultimate translation to clinical use remains challenging due to limited 
understanding of their true and dynamic activity in vivo. Within the context of combat-injury-
relevant therapies, this work examined the effect of the cellular environment on MPCs’ trophic 
and differentiation abilities.  
By varying the physical and cellular environment of MPCs in a context-dependent 
manner, it was hypothesized that a more thorough understanding of the robustness of 
regeneration- and clinically-relevant MPC-trophic and -functional activities would be obtained.  
The preceding chapters detailed attempts to describe MPCs and their therapeutic potential in the 
context of communications with other cell types, mainly ECs. The significant advantage of easy 
isolation and autologous sourcing of MPCs, as well as their angiogenic and neurotrophic effects, 
while promoting their potential therapeutic use, is counterbalanced by increasing evidence that 
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MPCs readily present a mineralizing phenotype under some of the same influences that were 
found to enhance MPC context-dependent trophic support. 
In the second chapter, which dealt with angiogenesis, it was found that MPCs 
preferentially promote angiogenesis in a manner distinct from and possibly superior to MSCs. 
This effect was likely due to MPC-secreted VEGF attracting ECs. MPCs are therefore likely to 
be useful in the recruitment of vasculature necessary to support an implanted construct. If 
encapsulated within a degradable hydrogel, viable and autologous MPCs could conceivably be 
used to facilitate any process requiring enhanced vascular support, including soft tissue or bone 
reconstruction in blast-traumatized limbs. Future investigations of MPC therapeutic potential as 
related to MPC angiogenic potential could examine adult animal models of vessel recruitment, as 
the CAM model involves extremely dynamic, embryonic vessels primed to form new blood 
vessels. 
In the third chapter, the described work added to the knowledge of neurotrophic functions 
of MPCs by investigating VEGF as an important MPC-produced neurotrophic factor. Distinctly 
higher VEGF production was seen in MPCs upon neurotrophic induction versus normal growth 
culture, and distinctly higher neurotrophic activity of MPCs was observed when their influence 
(either cell contact-mediated or through CM) was combined with that of ECs; together, both cell 
types preferentially supported the neurite extension of chick embryonic DRG, seeded on aligned, 
nanofibrous PCL nerve guide conduit and on tissue culture plastic. Selective removal of VEGF 
revealed a distinct but insignificant dependence of neurite extension on MPC-CM. This suggests 
that future conduit-based nerve therapies might best support nerve growth by encouraging the 
growth of neurovascular units versus nerves, alone. This hypothesis could be explored further 
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using MPCs implanted in a nerve guide conduit to support this strategy, but optimization of the 
scaffold and its effects on MPC neurotrophic function are still needed. 
 One possible mechanism to enhance neurotrophic cell-biomaterial interactions and 
neurotrophic support could be to coat the PCL fibers with ECM molecules. Laminin, collagen, 
and hyaluronic acid have all been shown to enhance nerve growth241. Pilot studies utilizing 
collagen and collagen-hyaluronic acid coatings on PCL fibers showed promising enhancement of 
neurite outgrowth without MPC influence, and when encapsulated within hyaluronic acid inside 
PCL conduits, MPCs and ECs appeared to exhibit increased neurotrophic molecule production 
and survival when cultured in combination than when cultured alone. 
The fourth chapter detailed work that ultimately suggests caution when approaching 
clinical, therapeutic use of MPCs. To summarize these findings, the osteogenic activities of 
MPCs in the context of a healing wound bed were explored, and MPCs were found to be a 
uniquely responsive mineralizing cell population. Early inflammatory markers, in the form of 
exogenous IL-1β, significantly increased MPC-mineralization but inhibited osteogenic gene 
expression, while EC influences, via contact-mediated and soluble factor, promoted a more 
mature osteoblast-phenotype capable of bony matrix deposition. Work in the fourth chapter 
suggested that this hyper-mineralizing phenotype might be due to the presence in MPCs of 
endothelial progenitor cells, which have been shown to positively influence fibroblast and MSC 
bone-forming abilities242. Given the intimate association between inflammation and wound 
healing, these findings suggest that any therapies involving MPCs would need to be tightly 
monitored for ectopic bone formation. Caution should therefore be applied in developing 
potential therapies, especially those that seek to restore skeletal tissue structure or function using 
MPCs. 
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The investigations presented here further solidify the view of MPCs as a trophic 
fibroblast with strong mineralizing potential. While primary isolates are known to be 
heterogeneous unless expanded unequivocally from a single cell progenitor243, evidence from 
this work and others indicates that MPCs represent an especially heterogeneous and dynamic 
mixture of plastic-adherent cells143. Clear differences were observed between MPC and MSC 
osteogenic and angiogenic activities, suggesting several areas of exploration. MPCs’ potent 
effects on and sensitivity to EC influence indicate that MPCs or a significant portion, likely the 
CD34+ faction, are highly-tuned to EC-derived signals. In particular, MPCs’ propensity to form 
bone in the presence of inflammation and angiogenic cell paracrine influence further solidifies a 
likely role in heterotopic ossification. Future work should investigate this role by examining the 
effect of transient versus chronic exposure to inflammation on the osteogenic phenotype of 
MPCs. 
This and other work have shown similarities and clear differences between MPCs and 
MSCs. While these differences are intriguing from a biological perspective, therapeutic 
relevance might be more easily found by comparing the different activities of blast-traumatized 
versus non-traumatized muscle-derived multipotent progenitor cells (MPCs vs. MD-MSCs) since 
blast-trauma appears to be the cause of distinctive disease pathologies. Work is ongoing to 
isolate a similar cell population from donor, non-traumatized cadaveric muscle for comparison to 
MPCs; however, differences in both donor age and muscle state (freshly debrided versus 
cadaveric) could contribute to unknown variation in MD-MSC activities. If a suitable blast injury 
mechanism could be introduced, an alternative comparison could be made using an animal 
model, allowing for direct blast-traumatized versus non-blast-traumatized muscle comparisons; 
work is ongoing to develop such a system utilizing cadaveric mice. 
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MPCs have proven to be an interesting study in the dual nature of multipotent cells 
within a wound environment. On the one hand, MPCs exhibit potent trophic activities, at times 
displaying superior vascular and sensory nerve support when compared to clinically nutilized 
MSCs. This support is evident even when MPCs are transferred from standard in vitro culture 
conditions to more clinically relevant constructs. Such therapeutic functions are highly desirable 
from the standpoint of the severely injured combatant and their medical care team. Mounting 
evidence, however, cautions against the consideration of MPCs as a combat-derived panacea. Of 
particular concern is that the chronically inflamed environment of blast–traumatized tissue may 
quickly restrict the differentiation potential of multipotent cells, and complicate culture-based 
attempts to direct MPC differentiation and, by extension, MPC-based therapies. This caution is 
based in part on our findings that additional or continuous exposure of MPCs to IL-1β, 
simulating an inflammatory environment, results in abnormal mineralization. However, it should 
be noted that this results from prolonged inflammatory influences. The insights gained from the 
above work suggest that work in the future should examine the response of MPCs to their 
environment, specifically the state of tissue inflammation; better control of inflammation is 
likely to be an important requirement for the development of MPCs for more effective MPC-
based therapies with fewer pathological complications. 
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APPENDIX A 
UTILIZED CELL POPULATIONS 
Table 4: Cell populations referenced in multiple chapters  
MPC1-3 were used for the work described in Chapters 3 and 4 while MPC1-4 were utilized in 
Chapter 2. MSC3-5 were utilized as control cell types for Chapter4. MSC 1-3 and 5 were utilized 
for Chapter 3. Initially, MPC derived from 7 patients were available for study. 3 patients were 
excluded due to low proliferation rates/early senescence by p.5. Upon extended passage, cell 
senescence in MPC4 was observed at p.8. 
 
 
 
In vivo cell source ID Isolation age (Years)  & gender Passage utilized 
Human blast-traumatized muscle 
Plastic-adherent cells134 
MPC1 
Individual patient data not 
available 
Total population description: 
24.4 ± 4, male  
3-10 
MPC2 3-10 
MPC3 3-10 
MPC4 3-8 
Bone marrow from femoral heads 
following arthroscopy 
Plastic-adherent244 
MSC1* 20, male 3-10 
MSC2* 20, male 3-10 
MSC3* 56, female 3-10 
MSC4* 60, male 3-8 
MSC5* 78, female 3-10 
Human foreskin fibroblasts [Lonza] HFF Neonates, male 5-8 
Human adult dermal microvascular 
endothelial cells [CDC]183,184 EC Immortalized cell line, male 5-8 
*Differentiation potential confirmed with in vitro adipogenic, osteogenic, and chondrogenic differentiation and colony-forming unit tests. 
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APPENDIX B 
GROWTH FACTOR RELEASE FROM METHACRYLATED-GELATIN 
CONSTRUCTS 
 
Figure 27: Growth factor release from photocrosslinked gelatin constructs  
Encapsulated FGF-2 and VEGF were readily released from the methacrylated gelatin constructs; 
this implies that cell-produced growth factors would also be rapidly released into the surrounding 
medium or tissue structures. 
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